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To Friends of the Department of Medicine
It has been another wonderful year in the Jefferson Internal Medicine
Residency Program. Our program continues to train the best and brightest
residents in the country. This publication is just one example of the passion,
dedication and creativity our residents continue to provide to the Jefferson
Community. The residents are not just outstanding clinicians but excel in all
aspects of medicine including: research, humanities and medical education.
Like every year, this year has seen changes in our training model as health
care delivery across the country continues to evolve. Besides being one of
the worst winters on record with our hospital bursting at the seams with
patients, we have also implemented a new training schedule called block
scheduling. This schedule has allowed us, as a program, to address work
compression in the hospital while prioritizing education in outpatient care
delivery. The Graduate Medical Education office in conjunction with our
residents and medicine faculty leadership is working to utilize the new EPIC
EMR to optimize patient care handoffs to improve safety and communication.
The residents are thought leaders in delivering outstanding care to our
patients across the spectrum and continue to challenge all of us to provide
quality, cost effective, safe care to our patients daily.
This journal, now in its 19th edition, continues to exemplify the perseverance,
inquisitiveness, and talent of our Internal Medicine residents. Congratulations
to the Editors and all of the residents who contributed to another amazing
edition of the Forum. I hope you will enjoy reading it!
Emily Stewart, MD, FACP
Associate Professor of Medicine
Program Director Internal Medicine Residency

From the
Editors

Dear Students, Residents, Faculty, and Friends of the Forum,
We are delighted to present you with the 19th annual edition of The Medicine Forum.
Here in the birthplace of our nation, we like to think of The Medicine Forum as being
of the housestaff, by the housestaff and for the housestaff. Undeniably, this publication
would not be possible without the countless hours dedicated by our residents,
students, fellows and faculty.
At its core, The Medicine Forum is about the expansion of our knowledge base
and the betterment of our clinical practice. In sharing our experiences with each
other, we all improve the care that we deliver our patients. With this objective in
mind, we are particularly excited to present you this year with a quality improvement
article on transitions of care. Dr. Turner and his colleagues tackle the handoff
processes between the intensive care units and the inpatient medicine services in
an effort to make these transitions safer for critically ill patients.
This year, we chose to highlight the opioid epidemic which has become the
greatest public health crisis of our generation. Working in the heart of Philadelphia,
we see the consequences of this epidemic every day. We see it in our clinics, in
our emergency department, and on our inpatient medicine services. Everyday, we
care for young patients with devastating complications of this disease. We struggle
with the challenges of treating addiction in the hospital and facilitating the
transition to outpatient care. In this edition, we talk to a team of multi-disciplinary
providers about the role of providers in this epidemic and how to best care for
these patients as we move forward. How we identify and respond to this crisis will
define our generation of medicine.
As always, thank you for reading the The Medicine Forum. We hope you will
continue to support us in the years to come.
Sincerely,
Neha Bansal Etherington, MD
Anita Modi, MD
Debbie Chen, MD
Brianna Shinn, MD
Colin Thomas, MD
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CLINICAL IMAGES

Clinical Image: Halo Sign
Brandon Menachem MD, and Alan Gandler MD

CASE PRESENTATION
A 68-year-old man with no significant past medical
history was transferred to our hospital for evaluation of
newly diagnosed acute leukemia. His bone marrow
biopsy showed acute undifferentiated leukemia. He was
initiated on standard induction chemotherapy with
cytarabine and idarubicin. His hospital course was
complicated by neutropenic fever secondary to
Fusobacterium bacteremia. He was started on antibiotic
th erapy with intravenous cefepim e an d oral
metronidazole. Intravenous vancomycin was added in
the setting of recurrent intermittent fevers. On hospital
day 20, he developed minimal hemoptysis, pleuritic
chest pain, and recurrent fevers. A CT scan of the chest
showed a right upper lobe band-like opacity. Due to
concern for possible invasive aspergillosis, he was
started on oral voriconazole. Serum galactomannan
was negative. Given the patient’s thrombocytopenia,
tissue diagnosis was deferred. Repeat CT of the chest
two weeks later showed an interval increase in the
right upper lobe spiculated mass with surrounding
ground glass “halo” (Figure 1). A presumptive diagnosis
of pulmonary aspergillosis was made in the setting of
prolonged neutropenia, classic symptomatology, and
rapid growth of the mass suggestive of an infectious
process, as well as the halo sign on CT. He was
discharged on voriconazole with plans for repeat
imaging in several weeks and possible tissue diagnosis
at that time.

Figure 2: A second case of the halo sign, often seen in early pulmonary aspergillosis
and aiding in prompt diagnosis in the correct clinical setting.

DISCUSSION
Members of the fungal genus Aspergillus have been
implicated as the causal organisms in a spectrum of
distinctive pulmonary pathologies in humans, including
allergic bronchopulmonary aspergillosis (ABPA), chronic
pulmonary aspergillosis, and invasive aspergillosis. The
extent of infection is largely determined by differences in
the host immunity-microbe interaction. Invasive
aspergillosis primarily occurs in the setting of immune
compromise, most commonly with acute leukemia,
recent hematopoietic stem cell transplant, neutropenia,
solid organ transplant on immunosuppression, and
chronic granulomatous disease. Pulmonary symptoms
typically include dyspnea, cough, and fever unresponsive
to broad-spectrum antibiotics. Pleuritic chest pain and
hemoptysis can occur due to vascular invasion. If
uncontrolled, Aspergillus can spread hematogenously
and seed all organ systems.
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Figure 1: The halo sign, as seen in our patient, is a nodule surrounded by ground
glass representing angioinvasive pulmonary infection

5

Diagnosis can be difficult since the only definitive tests
are biopsy with positive histopathology or positive
cultures from a normally sterile location. Since biopsy is
often not performed, infection must often be presumed
on the basis of clinical suspicion, respiratory culture data,
and biomarkers such as galactomannan. A positive
respiratory culture is not sufficient for diagnosis since
Aspergillus is a common colonizer. In addition, negative
cultures do not rule out infection. In immunocompromised or neutropenic hosts, fever may be the only
presenting symptom. Patients with persistent fevers
despite an appropriate course of empiric antibiotics
(10-14 days) should be assessed for potential fungal
infection. In patients for whom aspergillosis is suspected,
CT scan may help in identifying early invasive disease
and, as some studies suggest, lead to earlier initiation of

antifungal therapy and better overall outcomes. The
earliest findings on CT are pulmonary nodules and the
classic halo sign.
The halo sign is a nodule with surrounding ground glass
opacity. It is thought to represent a central area of
infarction and coagulative necrosis with surrounding
alveolar hemorrhage due to angioinvasion and local
pathogen spread. Although statistics vary between
reports, one of the largest cohorts included 235 patients
with proven or probable invasive disease, of which 94%
had a macronodule and 60.9% had a positive halo sign.
The halo sign is not pathognomonic for invasive
aspergillosis, as it has also been described with other
angioinvasive organisms including pulmonar y
Mucormycosis and Pseudomonas. However, Aspergillus
is the most common pathogen in those at risk for
invasive fungal infection. Aspergillosis may also present
as a bronchopneumonia, which may be indistinguishable
from other more common causes. Treatment consists
of a 6 to 12 week course of voriconazole.

This article serves to provide several examples of the halo
sign as seen in patients with acute leukemia and
neutropenic fever (Figures 1 and 2). Prompt identification
of this characteristic radiographic finding and initiation of
early treatment for invasive pulmonary aspergillosis is
important as mortality rates from untreated infection
range from 29-90% depending on patient characteristics.

REFERENCES
1. Segal BH. Aspergillosis. N Engl J Med. 2009;360(18):1870-84.
2. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute
invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin
Infect Dis. 2007;44(3):373-9.
3. Kaufmann C. Diagnosis of Invasive Aspergillosis. In: UpToDate, Post, TW (Ed),
UpToDate, Waltham, MA, 2014.
4. Kaufmann, C. Epidemiology and clinical manifestations of invasive
aspergillosis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2014.
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Massive Pneumoperitoneum
Harry Wang, MD

CASE PRESENTATION
A 72-year-old man with a past medical history of
pancreatic adenocarcinoma status post biliary and
duodenal stent placement presented to the emergency
department for one week of cramping abdominal pain
in the setting of a surveillance abdominal/pelvis
computed tomography (CT) scan done two days prior
to admission that showed massive pneumoperitoneum
(Figure 1). The patient felt bloated but otherwise had no
complaints on presentation. His physical exam was
significant for marked abdominal distension with mild
diffuse tenderness on palpation, normal bowel sounds,
and no peritoneal findings of guarding or rebound. Given
concern for perforated viscus causing pneumoperitoneum, he was started on intravenous antibiotics and
antifungal therapy. Repeat CT scan on admission
demonstrated patent biliary and duodenal stents and no
definite source of perforation. The patient remained
hemodynamically stable throughout his hospitalization;
he continued to have regular bowel movements daily
and eventually tolerated a diet. His abdominal distension
and pain gradually improved without any surgical
intervention, and he was discharged home six days after
admission to complete 7 days of oral fluconazole,
levofloxacin, and metronidazole. It was thought that this

1A

patient most likely had a perforated viscus that sealed off.
A CT scan two months later showed complete resolution
of the pneumoperitoneum.

DISCUSSION
Pneumoperitoneum is caused by perforated intraabdominal viscus in about 90% of cases, often requiring
acute laparotomy/laparoscopy for source control and
intravenous antibiotics for 4 -8 days to prevent
contamination of the peritoneal cavity.1 However, there
are reported cases of pneumoperitoneum without
peritonitis that resolve with conservative treatment. 2
These cases of “spontaneous” pneumoperitoneum
illustrate the importance of recognizing peritoneal signs
and deferring surgical intervention for those who would
otherwise have a benign clinical course.

REFERENCES
1. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial
therapy for intraabdominal infection. N Engl J Med 2015;372(21):1996–2005.
2. Williams NM, Watkin DF. Spontaneous pneumoperitoneum and other
nonsurgical causes of intraperitoneal free gas. Postgraduate Medical Journal
1997;73(863):531–7.

1B
Figure 1. CT abdomen/pelvis with contrast in the axial (1A) and sagittal plane (1B) showing massive pneumoperitoneum.
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Roth Spots in Bacterial Endocarditis
Michael A. Weintraub, MD

CASE PRESENTATION
A 30-year-old female with a history of intravenous drug
use presented to the hospital with left wrist pain. Physical
exam revealed a left volar ulnar wrist abscess with purulent
drainage, a holosystolic murmur heard best at the apex
radiating to the axilla and Janeway lesions on the right
hand and bilateral feet. A transthoracic echocardiogram
revealed a 20 mm mobile vegetation on the mitral valve
along with valve perforation and severe regurgitation
consistent with bacterial endocarditis.
On eye exam, Roth spots (Figure 1) were noted bilaterally.
Roth spots are present in less than 2% of all infective
endocarditis cases and are composed of immune
complex microthrombi that lead to a localized vasculitis.
Roth spots are one of the immunologic phenomena that
make up the modified Duke criteria in endocarditis but
they also appear in other conditions such as leukemia and
diabetes. The patient continued to develop more Roth
spots, however she did not experience any vision changes.
Brain MRI revealed multiple septic emboli and abscesses.
CT angiogram of the head revealed multiple foci of
contrast outpouchings consistent with mycotic aneurysms.
Her course was complicated by a spontaneous mycotic
aneurysm rupture which required endovascular coiling.

Figure 1. Roth spots are white-centered retinal hemorrhages. Roth spots were noted
bilaterally on our patient’s eye exam.

DISCUSSION
In endocarditis, surgical valve repair is indicated in the
setting of embolic events therefore she ultimately
underwent bioprosthetic mitral valve replacement. The
mitral valve culture was positive for propionibacterium
acnes, a rare cause of endocarditis (1% of cases). Wrist
abscess cultures grew clostridium perfringens and
streptococcus viridans which suggested polymicrobial
endocarditis. However, polymicrobial endocarditis was
thought to be less likely since the mitral valve cultures
only grew P. acnes.
As a member of normal skin and mouth flora, the
pathogenic potential of P. acnes is often overlooked. It is
a fastidious organism that presents commonly with
negative blood cultures, as seen in our patient. The
majority of patients with P. acnes endocarditis are
middle-aged males with prosthetic cardiac devices. This
case is unique given the patient’s demographics, the
causative organism, and the classic exam findings seen
in endocarditis.
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Sharon Li, MD

CARDIOLOGY

Acute Aortic and Mitral Valve Insufficiency
Precipitated by Infective Endocarditis
Raj Patel, MD, Tatiana Bekker, MD, and Daniel Kramer, MD

INTRODUCTION
Acute severe valvular regurgitation is a medical
emergency requiring prompt recognition and diagnosis.
Both mitral and aortic valve rupture, if left untreated,
inevitably lead to advanced heart failure, cardiovascular
collapse, and death. As such, rapid diagnosis is critical
and surgical valve repair or replacement is a life-saving
intervention. We present a case of a patient with both
mitral valve and aortic valve bacterial endocarditis who
developed acute valvular rupture, regurgitation, and
cardiovascular collapse.

CASE PRESENTATION
A 63-year-old male with no prior medical history
presented to an outside hospital with shortness of
breath, fatigue, and unexplained 30 pound weight loss
over three months. He noted some chills, but otherwise
denied fevers, night sweats, chest pain, or palpitations.
On admission to the outside facility, he was noted to be
hypoxic and admitted to the intensive care unit (ICU) for
respiratory failure. Chest computed tomography (CT)
was unrevealing. There was concern for a non-ST
elevation myocardial infarction (NSTEMI) for which a
cardiac catheterization was performed. No coronary
disease was noted on that study; however, it did reveal
severe aortic insufficiency and severe mitral regurgitation
with an ejection fraction of roughly 60%. Blood cultures
from admission showed Gram positive cocci in chains.
No vegetations were noted on transthoracic echocardiogram (TTE) or subsequent transesophageal echocardiogram (TEE). The patient was transferred to Thomas
Jefferson University Hospital (TJUH) for further
management of his valvular disease.
On presentation to TJUH, his physical examination was
notable for the following: thin male in mild respiratory
distress, without jugular venous distension. Rales were
present bilaterally on auscultation of the lungs. Cardiac
findings included tachycardia with a grade II/VI diastolic
decrescendo murmur heard at Erb’s point as well as a
grade III/VI holosystolic murmur at the cardiac apex
radiating to the axilla. A repeat TTE was done showing a
calcified mobile echodensity on the mitral valve with
mitral insufficiency and a mobile calcified echodensity on

the aortic valve with a flail leaflet and moderate to severe
aortic insufficiency. His admission chest x-ray showed
radiographic evidence of pulmonary edema. Blood
cultures from the outside hospital grew Streptococcus
gallolyticus subsp. pasteurianus (formerly Strep. bovis).
Repeat blood cultures at TJUH were without growth, but
the patient had been on antibiotics.
He was initially treated with diuretics for his edema, but
remained in mild respiratory distress. As such, he was
transferred to the cardiac ICU on hospital day 1 for closer
monitoring. As he was relatively hemodynamically
stable, appropriate preoperative work up was started and
he was planned for non-emergent cardiac surgery on
hospital day 8. On hospital day 5 however, his respiratory
status rapidly worsened. He initially improved with bilevel
positive airway pressure, but eventually decompensated,
requiring intubation. Immediately after intubation, he
became hypotensive, necessitating pressors. His post
intubation chest radiograph was notable for acute
pulmonary edema.

OUTCOME AND FOLLOW-UP
Cardiothoracic surgery was called and the patient was
taken for emergency cardiac surgery. Intraoperatively, the
right leaflet of the aortic valve was noted to be prolapsed
and perforated. This was ultimately excised. The mitral
valve was noted to have endocardial lesions involving the
coapting surfaces of both anterior and posterior leaflets,
and was also excised. Tissue valves were implanted to
replace the damaged aortic and mitral valves. Operating
room cultures of valvular tissue showed Gram positive
cocci on staining, but the organism was deemed
non-viable on repeat subculture.
Post-operatively the patient completed a 4-week course of
intravenous (IV) antibiotics. His course was complicated by
renal failure requiring dialysis and ventilator dependent
respiratory failure requiring tracheostomy and percutaneous
endoscopic gastrostomy (PEG) tube placement. Most
recently he was seen as an outpatient and was doing well
from a cardiac standpoint. He was no longer on dialysis
and both tracheostomy and PEG tube had been removed.
He was noted to be gaining weight and was able to walk
multiple blocks without becoming short of breath.
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DISCUSSION
The primary mechanisms by which acute aortic
regurgitation develops are endocarditis, aortic dissection,
and trauma. Acute regurgitation presents as a distinct
entity, quite different than the chronic form when the
ventricle has time to compensate for increased volume. In
acute aortic regurgitation there is a large reflux of volume
into an unprepared left ventricle. This reflux of volume
into a relatively small left ventricle rapidly increases the left
ventricular end diastolic pressure. Eventually this pressure
is transmitted to the left atrium and pulmonary circulation,
precipitating pulmonary edema. Additionally, there is
decreased cardiac output, which is exacerbated by two
mechanisms. The rise in end diastolic pressure mediates
a premature closure of the mitral valve thus shortening
diastolic filling time. Furthermore, the drop in cardiac
output will lead to a compensatory tachycardia that will
also decrease diastolic filling time.1
Patients typically present with signs of acute cardiovascular collapse (profound hypotension, pallor, cool
extremities) and acute pulmonary edema. Of note, due to
the acute volume and pressure overload, a functional
mitral regurgitation murmur may develop in the setting of
acute aortic regurgitation. However, this is different from
an organic cause of mitral regurgitation. It does not
warrant any intervention on the mitral valve and should
improve with repair of the aortic valve.1-3

The most common cause of acute valvular regurgitation
is endocarditis. Some studies show that it accounts for
>56% of cases of acute aortic regurgitation. 2 However,
encountering multi-valvular disease is overall less common
and has been estimated to account for only 15% of all
cases of all infective endocarditis. 4 The proposed
mechanisms theorize that there is secondary infection of
the mitral valve from either direct extension of the aortic
valve infection or a jet of regurgitant infected material that
progresses to a satellite infection.5 Cases of multi-valvular
endocarditis tend to be more complex and the majority
(~70%) require surgical intervention.4

KEY POINTS
Our patient presented with subacute, multivalvular
endocarditis with evidence of valvular insufficiency on
presentation. He initially appeared well compensated
without significant respiratory compromise. However, the
fragility of his valves placed him in a high-risk position.
Upon acute valvular rupture he rapidly decompensated
and required emergency cardiac surgery. Acute valvular
insufficiency is a medical emergency. Rapid identification
and triage, with referral for surgery, is a life-saving
intervention.

REFERENCES

Organic causes of acute mitral regurgitation, such as
endocarditis, do however require rapid intervention to
correct the valvular defect. Acute mitral valve rupture
leads to an acute regurgitation of fluid into a normal sized,
relatively small left atrium. This leads to acute pulmonary
edema and decreased forward flow.1-3

1. Hamirani YS, Dietl CA, Voyles W, Peralta M, Begay D, Raizada V. Acute aortic
regurgitation. Circulation 2012;126:1121-1126.

Definitive treatment of acute valvular insufficiency is
surgical repair. Temporizing medical measures can be of
limited benefit—primarily intravenous vasodilators, such
as nitroprusside, which promote forward flow by
reducing afterload.3 Inotropic agents such as dobutamine
can help as well.

4. Selton-Suty C, Doco-Lecompte T, Bernard Y, et al. Clinical and microbiologic
features of multivalvular endocarditis. Current infectious disease reports
2010;12(4):237-243.
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CARDIOLOGY

Cat Scratching Your Valve: An Elusive Case
of Bartonella Endocarditis
Ritu Nahar, MD and Evan Caruso, MD

INTRODUCTION
Bartonella Henselae is an uncommon, but significant
cause of “culture-negative” endocarditis. While six
Bartonella species have reportedly caused infective
endocarditis (IE) in humans, the vast majority of cases
are secondary to either B. quintana or B. henselae. The
epidemiologic features of patients predisposed to
Bartonella endocarditis are varied. Alcoholism, body lice
infestation, and homelessness have been associated
with B. quintana endocarditis, while B. henselae
endocarditis has been linked to prior valvular disease and
cat exposure.1-4 Patients with Bartonella endocarditis
have clinical manifestations similar to those seen with
traditional forms of subacute bacterial endocarditis.
However, the rarity of the disease compounded by
limitations of diagnostic testing make this entity a
diagnostic challenge. This case exemplifies a classic
presentation of Bartonella endocarditis while highlighting
the systemic repercussions of inadequate source control
and challenges associated with surgical intervention.

CASE PRESENTATION
A 53-year-old female with a history of dysautonomia
status post pacemaker over 10 years ago, membranoproliferative glomerulonephritis (MPGN), and chronic
pulmonary embolism (not on anticoagulation) presented
to an outside hospital with two years of fatigue, weakness,
and weight loss complicated by unexplained fevers for 2
weeks. The patient was initially treated with broad
spectrum antibiotics, but fevers persisted. Infectious
work-up at outside hospital was negative. Upon delving
further into her social history, the patient endorsed
extensive contact with cats, assisting in kitten birthing 6
months prior to presentation. Physical exam revealed a
2/6 systolic murmur at the left lower sternal border that
was louder with inspiration. On transthoracic echocardiography, a 2.2 x 1.9 echodensity was visualized adjacent
to the tricuspid valve in close proximity to the right
ventricular (RV ) pacemaker lead with smaller
echodensities on the atrial side of the RV pacemaker
lead. Broad-spectrum antibiotics were initiated but the
patient continued to spike fevers as high as 104° F. Blood
cultures remained sterile despite prolonged incubation
periods. Transesophageal echocardiography 5 days later
demonstrated progression of lesions, now revealing a
3.9 x 2.5 cm mass stemming from the RV pacemaker

lead. On the 5th hospital day, the patient developed
severe pleuritic chest pain. Computed tomography (CT)
of the chest demonstrated wedge shaped peripheral
opacities suspicious for lung infarct from septic emboli
versus thromboemboli.

DIFFERENTIAL DIAGNOSIS
Patients with valvular/pacemaker vegetations in the
absence of overt bacteremia typically result from
marantic endocarditis secondary to a noninfectious
etiology or culture-negative endocarditis from an
infectious source.5 Marantic vegetations (nonbacterial
thrombotic endocarditis) refers to a spectrum of lesions
generally seen in the setting of hypercoagulable states,
malignancy, and rheumatologic conditions including
s ystemic lupus er y thematosus (Libman -Sacks
endocarditis). Interestingly, our patient had a history of
pulmonary embolism diagnosed the year prior in the
setting of antithrombin deficiency which, compounded
by her biopsy proven MPGN, raised concern for a
possible thrombotic endocarditis or verrucous
endocarditis.
The leading causes for negative cultures in infective
endocarditis include prior antimicrobial treatment as
seen with our patient and insufficient microbiological
techniques. While HACEK organisms (Haemophilus
aphrophilus; Actinobacillus actinomycetemcomitans;
Cardiobacterium hominis; Eikenella corrodens; and
Kingella kingae) were conventionally believed to be
culture-negative, they have since been more successfully
cultured with the assistance of modern culture systems.6
Instead, the predominating causative agents of blood
culture-negative endocarditis are fastidious organisms
such as zoonotic agents and fungi. C. burnetii and
Bartonella species are two such pathogens with
prevalence based on exposure to epidemiological risk
factors. Of note, T. whipplei may also be an underappreciated source of culture-negative IE with Mycobacteria
being a rarer cause.7
Our patient underwent a thorough rheumatologic and
infectious work-up. Her extensive kitten exposure
combined with iatrogenic interruption of her valve
(pacemaker placement) significantly increased the risk
for a possible Bartonella infection. Diagnostic tests for
culture-negative endocarditis include unique culturing
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techniques, molecular tests including polymerase chain
reaction (PCR) and serologic assays, and lastly direct
histopathology staining of valvular tissue. She was found
to have positive Bartonella serology with an elevated
Bartonella henselae immunoglobulin G (IgG) level at
1:512. Interestingly, her B. Quintana IgG was also 1:512
likely secondary to cross-reactivity, which is common
between IgG among Bartonella species. Of note, the
recommended cutoff for definitive positivity in patients
with suspected Bartonella endocarditis is a titer of ≥1:800
for IgG antibodies to either Bartonella henselae or
Bartonella quintana.8 Diagnosis was eventually confirmed
by positive blood PCR for Bartonella.

added for additional coverage of culture-negative
endocarditis if definitive diagnosis of Bartonella has not
been established.10 Of note, our patient had actively
evolving lung infarction from septic emboli and recurrent
symptomatic fevers resulting in hemodynamic instability,
thus surgical removal of the pacemaker and leads was
indicated. While endocarditis is an established
predisposing factor for decreased heparin responsiveness
during cardiopulmonary bypass, the mechanism of this
phenomena and how this alters management pre and
intra-operatively is an area of research requiring further
evaluation.11

KEY POINTS
OUTCOME AND FOLLOW-UP
The patient was started on doxycycline (given continued
symptomatic fevers) and deemed appropriate for
pacemaker and lead removal. The decision was also
made to initiate anticoagulation given evolving lung
infarcts on CT. Management was complicated by heparin
resistance requiring antithrombin concentrate pre- and
intra-operatively. On hospital day 10, the patient
underwent successful cardiopulmonary bypass surgery
for pacemaker and associated mass removal. Of note, the
patient was not a candidate for percutaneous lead
extraction due to the size of her vegetation; thus, earlier
detection may have precluded necessitating surgical
intervention. Post-operatively she was initiated on a
6-week course of doxycycline, rifampin, and ceftriaxone.
Gentamycin was avoided given her renal impairment
from MPGN. Upon confirmation of Bartonella blood PCR,
ceftriaxone was discontinued and the patient completed
a 6-week course of oral doxycycline and rifampin.

DISCUSSION
This case highlights the importance of eliciting
epidemiologic risk factors when working up fevers of
unknown origin. Systemic complications our patient
endured from lack of prompt intervention include
recurrent hospitalizations and septic lung emboli.
Additionally, Bartonella endocarditis is associated with
development of immune-complex glomerulonephritis.9
Thus her MPGN may also in fact be a manifestation of
her untreated endocarditis. Blood cultures for Bartonella
henselae are seldom positive, potentially a result of
intraerythrocytic sequestration of the pathogen.
Therefore, specialized culturing, molecular assays, and
histopathological evaluation of valvular tissue are
generally required to establish the diagnosis.
Medical management for Bartonella endocarditis is
comprised of dual therapy with doxycycline and
gentamicin. Gentamicin may be replaced by rifampin if
the patient has renal impairment. Ceftriaxone can be
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Recognizing and appropriately diagnosing Bartonella
endocarditis is critical in preventing systemic
complications via earlier surgical intervention for source
control augmented with adequate antibiotic coverage.
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ENDOCRINOLOGY

Case Report: Coexistence of Papillary Thyroid
Cancer and Thyroid Lymphoma
Christine Mathai, MD and Edward Ruby, MD

ABSTRACT

DISCUSSION

We describe a case of a 75-year-old female found to have
concurrent papillary thyroid cancer and diffuse large B
cell lymphoma of the thyroid.

Papillary thyroid cancer is the most common thyroid
cancer, making up 70-80% of diagnosed thyroid cancers.2
The BRAF V600E mutation, which activates the mitogenactivated protein kinase (MAPK) signaling pathway, is
found in 40- 45% of papillary thyroid cancers. 3 BRAF
mutation screening is typically performed with FNA
biopsies of thyroid nodules to aid in the diagnosis of
papillary thyroid cancer. However, this mutation is found
in other thyroid malignancies as well, including thyroid
lymphomas. In one study reviewing 33 thyroid lymphomas
of various types, 8 of the 33 lymphomas were positive for
a BRAF mutation, including the V600E mutation, D594G
mutation, and K601N mutations.3 Of note, the presence
or absence of the BRAF mutation did not change
outcomes. These patients were treated with a combination
of surgery, radiation, and/or chemotherapy with an overall
33% mortality from their respective thyroid lymphoma.

CASE PRESENTATION
A 75-year-old female presented to the hospital with
weakness and a 35-lb weight loss over a 6-month
period. She was found to have a new diagnosis of Type
2 diabetes and was evaluated by endocrinology. Physical
exam was notable for a palpable right sided thyroid
nodule. Thyroid stimulating hormone (TSH) was normal.
Thyroid ultrasound confirmed a 4 x 4.8 cm nodule in
the right lobe. Fine needle aspiration (FNA) of the nodule
revealed atypia of undetermined significance, but the
sample tested positive for BRAF and NRAS mutations,
concerning for papillary thyroid cancer. She underwent
total thyroidectomy. Pathology revealed a combination
of multifocal papillary carcinoma, diffuse large B-cell
lymphoma (DLBCL) of the thyroid, and chronic lymphocytic
thyroiditis. Post-thyroidectomy, she was started on oral
levothyroxine to maintain a euthyroid state.
Follow-up positron emission tomography/computed
tomography (PET/CT) scan showed no fluorodeoxyglucose (FDG) uptake in the neck, chest, abdomen, and
pelvis. Several 2-3 mm nodules were found in both upper
lobes of the lung, some of which demonstrated minimal
cavitation which were nonspecific and likely infectious or
inflammatory in origin. Metastatic disease in the lung was
considered unlikely given the upper lobe predominance.
Her DLBCL was characterized as stage IE.
She followed up with medical oncology for management
of her DLBCL. She was initiated on standard of care for
her disease, including a combination of chemotherapy
with 3 cycles of R-CHOP and local radiation, which
reportedly has a 90-95% 5-year overall survival rate for
stage I extra-nodal DLBCL. 1 She is following with
endocrinology for her stage I papillary thyroid cancer,
now status-post total thyroidectomy, and continues to
take levothyroxine for thyroid replacement. After her
treatment for lymphoma is complete, the need for
radioactive iodine (RAI) treatment would be discussed
further between oncology and endocrinology.

In comparison to papillary thyroid cancer, primary thyroid
lymphomas are rarer, accounting for less than 5% of all
thyroid cancers or 2 cases per million.2,4 Primary thyroid
lymphomas are typically B-cell in origin and affect
middle-aged to older individuals, primarily women. They
usually present as rapidly growing neck masses and less
commonly present with compression symptoms or
B type symptoms. Patients usually present with Stage I
disease. Diffuse large B-cell lymphoma is the most
common subtype of thyroid lymphoma; mucosaassociated lymphoid tissue (MALT) lymphomas are the
second most common.4 Of thyroid lymphomas, MALT
lymphomas tend to be more indolent in nature with a
favorable prognosis. MALT lymphomas localized to the
thyroid gland tend to respond well to total thyroidectomy
and radiation but about 40% of diffuse B-cell lymphomas
evolve from MALT lymphomas.2 The 5-year survival of
diffuse B-cell lymphoma is less than 50% with treatment,
including chemotherapy and radiation.2 This increases
the importance of early diagnosis of thyroid lymphoma.
There is an association between papillary thyroid cancer
and MALT lymphoma in the setting of Hashimoto’s
thyroiditis.2 MALT lymphomas in particular are difficult to
distinguish from Hashimoto’s thyroiditis on FNA biopsy as
they are histologically similar. Hashimoto’s thyroiditis has
been associated with 10-58% of cases of papillary thyroid
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cancer and more than 90% of cases of thyroid lymphoma.2
However, the co-occurrence of papillary thyroid cancer
and thyroid lymphoma is very rare.2 This case demonstrates
that as a clinician, one must be aware of the possibility of
multiple concurrent thyroid malignancies.
Of note, our patient was never diagnosed with thyroiditis
prior to her presentation, but had evidence of chronic
thyroiditis on final pathology. Because of the association
of thyroid malignancy in patients with Hashimoto’s
thyroiditis, there should be adequate surveillance in
patients with a history of Hashimoto’s thyroiditis for
papillary thyroid cancer as well as thyroid lymphoma.
Some studies suggest performing a thyroid ultrasound at
the initial visit for patients diagnosed with Hashimoto’s
thyroiditis to screen for thyroid malignancy.5 Although,
the risks and benefits of this type of surveillance would
likely need to be studied further. In addition, testing for
BRAF, NRAS and a growing list of other genetic mutations,
particularly in patients with atypia of undetermined
significance on FNA biopsy, is becoming more prominent
in the identification of thyroid malignancies.6 These
mutations are frequently present in papillary thyroid
cancer, but are also seen in thyroid lymphoma, making
it important to consider thyroid lymphoma in the
differential diagnosis when these mutations are detected
in thyroid FNA samples.7
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Octreotide-Induced Hypoglycemia in a
Cirrhotic Patient
Debbie Chen, MD

INTRODUCTION

CLINICAL MANAGEMENT

Hepatorenal syndrome (HRS) is characterized by
functional renal impairment in patients with end-stage
liver cirrhosis and no parenchymal kidney disease. It is
due to splanchnic vasodilation, which results in renal
vasoconstriction with consequent reduction in renal
plasma flow and glomerular filtration rate.1 In the United
States, treatment is with a combination of octreotide,
midodrine, and human albumin to increase the effective
blood volume and subsequently improve renal function.2
While octreotide, a long-acting somatostatin analog, is
used to induce splanchnic vasoconstriction in this setting,
it also affects the secretion of insulin and glucagon.

The patient was briefly treated with high-dose octreotide
(up to 200mcg every 8 hour), hydrochlorothiazide, and
diazoxide when the etiology of his hypoglycemia was
thought to be a result of excess insulin secretion. The
hydrochlorothiazide and diazoxide were discontinued in
the setting of hyperkalemia and worsening kidney
function. There was no appreciable improvement in the
patient’s blood glucose levels until the octreotide was
discontinued and high-dose steroids was initiated. The
patient was weaned off of all continuous dextrose infusion
about three weeks after he last received octreotide, and
was subsequently discharged home one week later on
prednisone 5mg once daily. As an outpatient, the patient
was tapered off of prednisone.

CASE PRESENTATION
A 44-year-old man with a history of Roux-en-Y gastricbypass and alcoholic cirrhosis complicated by ascites and
esophageal varices status-post banding was transferred
from an outside hospital for management of hepatic
encephalopathy, which clinically improved with lactulose
and rifaximin administration. He was recently diagnosed
with acute on chronic kidney injury from presumed type
2 hepatorenal syndrome, and started on octreotide,
midodrine, and albumin. His hospital course was
complicated by persistent symptomatic hypoglycemia
that required him to be on a continuous dextrose 50
percent in water infusion, and a high-carbohydrate diet.
Laboratory Studies: When the patient was symptomatically hypoglycemic with a blood glucose level of 43 mg/
dL, he concurrently had elevated levels of serum insulin
(25 mcIU/mL), C-peptide (10.38 ng/mL), and pro-insulin
(52 pmol/L).
Radiological Findings: Abdominal ultrasound and
magnetic resonance imaging studies showed no gross
evidence of a pancreatic mass. The initial somatostatin
receptor scintigraphy showed increased activity in the
region of the pancreatic head and uncinate process with
focal uptake in the dome of the liver. However, a repeat
somatostatin receptor scintigraphy about two weeks later
showed resolution of the previously noted increased
activity. Intra-arterial calcium stimulation with hepatic
venous sampling showed no evidence of elevated insulin
levels, significant vascular disease, or a hypervascular
region. All of these studies were unrevealing for evidence
of a neuroendocrine tumor.

DISCUSSION
In the evaluation of hypoglycemia in patients without
diabetes, it is essential to first distinguish between those
that meet criteria for Whipple’s triad from those who do
not, as the former group requires further laboratory
workup. Whipple’s triad consists of a low plasma blood
glucose concentration with concurrent symptoms of
hypoglycemia, and symptomatic improvement after the
blood glucose level is raised.
In our patient who had documentation of Whipple’s triad,
the differential for the etiology of his hypoglycemia
included an insulinoma, nesidioblastosis, and side effect
of octreotide administration. Nesidioblastosis after gastricbypass surgery causes hyperinsulinemic hypoglycemia as
a result of pancreatic islet cell hypertrophy.3 Laboratory
evaluation was consistent with those expected in an
insulinoma given elevated levels of serum insulin,
C-peptide, and pro-insulin when the patient’s blood
glucose level was 43 mg/dL. However, repeat octreotide
scans and portal venous sampling did not yield evidence
of a neuroendocrine tumor.
Octreotide inhibits insulin secretion, and is thus indicated
in the treatment of sulfonylurea-induced hypoglycemia.
However, paradoxical hypoglycemia with octreotide use
has been described in case reports of patients with an
insulinoma and a proinsulinoma. 4-7 In our patient,
octreotide-induced hypoglycemia is the most plausible
explanation for his persistent hypoglycemic state, which
spontaneously resolved without additional intervention
after discontinuation of octreotide.
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Liver Abscess Turned Metastatic Infection in an
Otherwise Healthy Patient: A Case Report
Samik Shah, MD, Ritu Nahar, MD, and Neha Etherington, MD

INTRODUCTION
The most common type of visceral abscesses are liver
abscesses, which have a mortality rate of at least 2.5
percent. 1,2 Most liver abscesses are polymicrobial,
containing both facultative and anaerobic enteric
pathogens, and develop secondary to another infection
such as peritonitis and cholangitis, or from hematogenous
spread.2-4 Liver abscesses are sometimes associated with
systemic diseases such as colorectal cancer and diabetes
mellitus.5,6 Rarely, as in our case presentation, primary liver
abscesses occur spontaneously in patients with no
identifiable precipitating or predisposing conditions.

CASE PRESENTATION
A 54-year-old Chinese-American woman with no
significant past medical history presented to the
emergency room with two weeks of subjective fevers
and chills that worsened two days prior to presentation.
She denied shortness of breath, chest pain, abdominal
pain, nausea, vomiting, diarrhea, and dysuria. She had no
prior surgeries and took no medications. She did not use
tobacco, alcohol, or illicit drugs and she worked in a
restaurant. She immigrated to the United States from
China in the 1990s, and recently traveled to China six
months prior to admission.
In the emergency room, she was febrile to 101.6°F,
tachycardic to 128 beats/minute, and hypotensive to
85/53 mmHg. Physical exam revealed cervical lymphadenopathy. She was not jaundiced, had no abdominal
tenderness or distension, and had a non-focal neurologic
exam. Laboratory studies were notable for an elevated
leukocyte count 15.2 B/L, aspartate aminotransferase 142
IU/L, alanine aminotransferase 189 IU/L, alkaline
phosphatase 295 IU/L, and total bilirubin 1.3 mg/dL.
Abdominal ultrasound showed nonspecific gallbladder
wall thickening and sludge without biliary ductal dilatation
or pericholecystic fluid. Blood cultures were drawn. She
was treated with fluid resuscitation and antibiotics
(vancomycin, piperacillin-tazobactam, and one dose of
tobramycin) for presumed sepsis.
Within 24 hours, blood cultures became positive with
gram-negative bacilli, so vancomycin was stopped.
Soon after, the patient developed nausea, vomiting, and
a brief new oxygen requirement of 2 L/min via nasal
cannula. Chest x-ray revealed a new (since admission)
small opacity in the left lung base. Respiratory pathogen
panel, rapid influenza and respiratory syncytial virus

Figure 1. Computed tomography scan of the abdomen with intravenous contrast
showing the abscess at the dome of the liver (arrow).

nasal swab, and urine Streptococcal and Legionella
antigens were all negative.
On day three of admission, the initial blood cultures
speciated as Klebsiella pneumoniae. On day four, she
developed vertigo with left ear hearing loss, tinnitus,
nausea, and vomiting. Dix-Hallpike maneuver was
positive, but the rest of the neurologic examination was
non-focal. Repeat blood cultures were persistently
positive for the same organism.

DIFFERENTIAL DIAGNOSIS
The patient presented with sepsis from K. pneumoniae
bacteremia that was complicated by hypoxia. Even with
the hypoxia considered, K. pneumoniae is not a common
cause of community acquired pneumonia in an
otherwise healthy patient, and the patient had sustained
bacteremia despite treatment with appropriate
antibiotics. Her hypoxia was thus attributed to aspiration
due to her emesis. Although a primary source for
Klebsiella bacteremia may not be identified in up to
30-47 percent of patients, this is more common in
nosocomial rather than community acquired infections.7
Community acquired bacteremia from primary liver
abscesses is well-documented in the East Asian
population.8,9 Further, primary Klebsiella liver abscesses
can rarely be complicated by metastatic brain abscesses.10
In the setting of our patient’s sustained bacteremia with
new onset vertigo, she underwent imaging of the brain,
abdomen, and pelvis to rule out the presence of abscesses.
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OUTCOME AND FOLLOW-UP
Computed tomography (CT) of the abdomen and pelvis
showed a 5.3 x 4.6 cm abscess at the dome of the liver
(Figure 1). CT of the head showed multiple subcortical
ring-enhancing lesions (largest measuring 12 mm) that
were concerning for cerebral abscesses. Magnetic
resonance imaging (MRI) of the brain similarly showed
multiple cerebral abscesses. The cerebral abscesses were
determined to be too small for neurosurgical intervention.
MRI of the whole spine was unremarkable. Her antibiotics
were narrowed from piperacillin-tazobactam to ceftriaxone
for better central nervous system penetration. On day five
of admission, she underwent liver abscess drain placement
with fluid culture positive for K. pneumoniae. The liver
abscess drain was removed after four days because of
decreased output.
After the drain placement, blood cultures cleared and
remained negative. Repeat brain MRI performed six days
after the initial scan showed that some lesions increased
and others decreased in growth, and that there was a
new punctate foci of enhancement. Neurological exam
remained non-focal. On day 13, she was discharged
home to complete a six-week course of intravenous
ceftriaxone. Post-discharge imaging shows resolution of
the liver abscesses. Unfortunately, she had persistent
tinnitus and difficulty hearing on the left side, so she sees
an audiologist.

KEY POINTS
This case highlights the importance of a broad differential
diagnosis when evaluating a patient with an unknown
source of bacteremia. A Klebsiella liver abscess should be
considered in East Asian patients without an identified
source of bacteremia. Early detection to prevent central
nervous system metastasis can prevent further devastating
complications. The identification of our patient’s liver
abscess allowed for source-directed therapy with
immediate drainage and subsequent resolution of the
patient’s bacteremia.
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pain, nausea, and vomiting. The most common laboratory
abnormalities involved the initial serum albumin (mean
3.1 g/dL, 70% of patients had an abnormal value),
leukocyte count (15.4 B/L, 68%), alkaline phosphatase
(206.8 IU/L, 67%), and alanine aminotransferase (93.4
IU/L, 54%).2 Treatment of the liver abscesses involves
drainage of the abscess to obtain source control.
Antibiotics should be tailored to the sensitivities of the
Klebsiella species, with a duration of at least a four to six
weeks. Follow-up CT imaging is recommended to ensure
resolution of the abscesses.
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Maggots—Friend or Foe? Treating Myiasis in a
Patient with Chronic Wounds
James Harrigan, PharmD, Anita Modi, MD, and Gretchen Diemer, MD

INTRODUCTION
Myiasis, or the infestation of living vertebrates with
dipterous (two-winged fly) larvae, can take many forms.
Depending on their species, maggots will feed on living
or dead tissue, liquid body substances, or even ingested
food.1 The anatomical classification system of such larvae
is based on the host location of infestation: sanguinivorous, cavitary, or cutaneous, including furuncular,
migratory, or wound.1 While pathologic myiasis can result
in significant morbidity in both humans and livestock,
therapeutic myiasis has played an important role in
wound debridement for centuries. This article will explore
the varying forms of pathologic cutaneous myiasis and
the evolving role of therapeutic myiasis by presenting the
case of a patient admitted with newly identified infestation
of bilateral lower extremity wounds.

Figure 1. Superficial lower extremity wounds without purulence, edema, erythema,
or other evidence of superimposed bacterial infection.

Table 1: Diptera larval species responsible for varying forms
of cutaneous myiasis.
Cutaneous Myiasis

Diptera Larval Species

Furuncle Myiasis

Dermatobia
Cordylobia
Cuterebra s
Wohlfahrtia
W opaca

Migratory Myiasis

Gasterophilus
Hypoderma spp.

Wound Myiasis

Facultative
Lucilia seriata
Obligatory
Cochliomyia
Chrysomya
W magnifica

hominis
anthropophagia
pp.
vigil
intestinalis
parasites
parasites
hominivorax
bezziana

consulted for potential debridement. However, it was
noted on inspection that his extremities were devoid of
any necrotic tissue to debride. The lack of necrotic tissue
was attributed to the maggot infestation. Topical betadine
solution was applied and two doses of ivermectin 400
mcg/kg/dose were administered to treat concomitant
body lice. Three days after initiation of these therapies,
the wounds began to exude purulent and malodorous
drainage with evidence of newly developed necrotic
tissue. Local wound care with daily dressing changes
incorporating Santyl (collagenase), Medihoney, and
betadine-soaked gauze were continued for the remainder
of the hospital course to prevent further infection.

CASE PRESENTATION

DISCUSSION

The patient is a 59-year-old homeless man with a history
of poorly-controlled schizophrenia who presented to the
Thomas Jefferson University Hospital (TJUH) Emergency
Department with bilateral leg pain. On examination, his
legs had multiple areas of superficial ulceration with pale
larvae (Figure 1). There was no purulent drainage to
suggest superimposed bacterial infection, and his vital
signs and laboratory studies demonstrated no signs of
systemic illness. The patient was admitted for management
of necrotic wounds complicated by myiasis. Surgery was

Pathologic myiasis is most frequently seen in tropical
and travel medicine settings, though maggots can be
easily found all over the world, including the United
States.2 Cutaneous myiasis—furuncular, migratory, or
wound—is the fourth most reported skin disease in
returning travelers.3 Poor hygiene and low socioeconomic
status, which were noted in our patient, serve as risk
factors for pathologic myiasis even in developed
countries. 4 Wounds most susceptible to pathologic
myiasis include neuropathic ulcers, vascular insufficiency
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ulcers, psoriasis, hemorrhoids, impetigo, and malignant
wounds. 4 Given its prevalence, an understanding of
identifying and treating various forms of cutaneous
myiasis and superimposed bacterial infections such as
tetanus is important.
Furuncular myiasis develops following larval penetration
into the healthy exposed skin of travelers or inhabitants of
tropical regions, with an incubation period of one to two
days. A pruritic, painful, and erythematous nodule forms,
with a central dimple facilitating larval respiration and
releasing serosanguinous or purulent fluid—and through
which a single or multiple larvae can be directly observed.5
Agitation and insomnia can occur even in localized
myiasis, while systemic symptoms of fevers, chills, and
lymphadenopathy suggest secondary bacterial infection.
While larvae responsible for furuncular myiasis tend to
stay localized within the primary nodule, those of
migratory myiasis burrow through the skin and lead to the
development of pruritic lesions with raised red borders.4
These erythematous lesions that are the result of initial
larval infestation fade to yellow patches once the larva
migrates to a new site. In so doing, larvae can live for
months in human skin, rarely penetrating visceral organs
and brain and lung parenchyma. Migratory myiasis is
typically associated with animal exposures, as the Diptera
species involved cannot complete their larval life cycles in
human hosts and instead relies on cattle and horses as
intermediate hosts.
Wound myiasis, such as was seen in our patient, results
when flies occupy and lay eggs in open wounds, especially
those with necrotic, hemorrhaging, or purulent lesions.4
Facultative parasites feed only on dead tissue within a
wound, excrete antimicrobial and alkaline substances to
inhibit bacterial growth, and stimulate granulation—
providing utility in wound debridement for centuries.6
Obligatory parasites, on the other hand, require living
tissue for larval development, and are thus prone to cause
local destruction, fistula formation, as well as invasion of
deep tissue requiring immediate removal.5 Examination of
the wound itself can help determine whether the larvae are
facultative or obligatory. Facultative parasites often remain
superficial and visible to the naked eye, consuming necrotic
tissue on a microscopic level to leave behind clean margins
and healthy granulation tissue. Obligatory parasites
produce foul-smelling discharge, localized swelling, and
deep pockets of infection. Therapeutic myiasis involves the
careful selection and sterile harvesting of facultative
species, such as Lucilia sericata, which will effectively serve
to debride, disinfect, and enhance healing at the wound
site (Table 1). Clinical indications for the use of therapeutic
myiasis include wounds infected with multi-drug resistant
bacteria, superficial wounds, non-healing ulcers and burns,
and the presence of significant medical comorbidities
precluding surgical debridement. Exudate, wound odor,
and pain sores have all been demonstrated to decrease
with therapeutic myiasis when compared to conventional
dressings.6 All studies to date have used laboratory-bred
sterile maggots; no studies to our knowledge have
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evaluated outcomes in patients presenting with wounds
already infested with maggots.
Diagnosis of pathologic myiasis is usually clinical, although
dermoscopy and ultrasound have been employed in the
detection of larvae within furuncular lesions and along
migratory tracts.4 Peripheral eosinophilia and elevated IgE
levels may be observed in patients with chronic or recurrent
myiasis, though these values may be normal in the context
of acute infestation. Once identified, pathologic larvae
should be killed using one of three techniques: application
of a toxic substance to the larvae; production of localized
hypoxia (i.e. via occlusion of the central dimple with
petroleum or paraffin) to force the larvae to emerge from
the furuncle; or mechanical/surgical removal of the larvae.4
Regardless of the mechanism of killing employed, dead
larvae should be removed to prevent secondary bacterial
infection. Systemic therapy is not recommended for
furuncular myiasis in the absence of secondary bacterial
infection, as dead larvae may remain trapped within the
nodule, resulting in a subsequent inflammatory reaction
and development of a nidus.4 Eradication of obligatory
parasites in wound myiasis is similarly performed on a local
level, involving application of antiseptic solution or topical
ivermectin to the wound. In addition, oral ivermectin or
albendazole have been reported to bring migratory larvae
closer to the skin surface facilitating subsequent extraction.

KEY POINTS
Therapeutic myiasis has long been employed in controlled
settings for the management of chronic, poorly-healing
wounds. Enzymes found in the gastrointestinal tracts of
some species confer antimicrobial properties to this
localized therapy. However, it should be stated that not all
maggots are created equal. Obligate larvae feed on all
tissues thereby endangering human hosts, while facultative
larvae feed preferentially on necrotic tissues—making
them ideal therapeutic agents. Despite being used with
great regularity for local wound care in ancient cultures,
the mere thought of maggots has made many physicians
shudder since the advent of germ theory in the second
half of the 19th century.6 While it has yet to be definitively
proven in any scientific studies, preserving and identifying
maggots that prefer necrotic over living tissue could help
debride extensive wounds and allow for timely healing.
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GENERAL MEDICINE

When DeQuervain’s DePigments:
A Case of Iatrogenic Hypopigmentation
Tatiana Bekker, MD

INTRODUCTION
Localized joint and soft tissue corticosteroid injections
are being increasingly utilized to decrease inflammation,
improve pain, and recover mobility. Adverse effects
from injections are rare, with a 1% incidence of skin
depigmentation.1

CASE DESCRIPTION
A 58-year-old African American female initially presented
to her outpatient primary care clinic with a chief complaint
of left wrist pain. She described the pain as localized over
the lateral aspect of the radiocarpal joint, non-radiating,
and without overlying erythema or edema. The pain had
been present for five months. The patient had already
tried NSAIDS as well as splinting with minimal relief.
On physical exam, the patients’ wrist, hand, and fingers
appeared normal to inspection. On palpation, joint spaces
were non-tender; however, her Finkelstein’s test was
grossly positive. This raised suspicion for pathology in the
1st and 2nd extensor compartments consistent with De
Quervain’s tenosynovitis. All therapeutic options were
explained to the patient and she agreed to receive a
steroid injection, as this has been shown to have superior
outcomes for De Quervain Tenosynovitis.1,2 Consent was
obtained and 10mg triamcinolone was injected in the
region of the first extensor compartment just proximal to
the radiocarpal joint.3
The patient experienced mild symptomatic relief for
approximately four weeks. Four months later, she returned
to the clinic with skin depigmentation over her left wrist
(Figure 1). On exam, her skin was neither pruritic, inflamed,
nor painful to palpation. No other areas of depigmentation were appreciated.

DIFFERENTIAL DIAGNOSIS
The differential diagnosis of acquired skin hypopigmentation includes vitiligo, pityriasis alba, tinea versicolor,
post inflammatory causes, and iatrogenic (i.e. from
steroids, both injected and less commonly topical). 4
Pityriasis is typically found on the face, neck, and arms
and is most commonly associated with a history of
atopic dermatitis.5 Vitiligo is an autoimmune disorder that
classically presents with a diffuse bilateral distribution of
skin depigmentation and is not limited to skin alone—as

Figure 1. Skin depigmentation over the patient’s left wrist.

hair and mucosal depigmentation may be appreciated as
well.6 Tinea versicolor, a fungal skin infection, presents
with multiple diffuse patches as well, most commonly
presenting on the trunk.7 For this specific patient, the
localized area of depigmentation and recent steroid
injection made iatrogenic cause the most likely etiology.

OUTCOME AND FOLLOW UP
Available therapies for De Quervain’s tenosynovitis include
rest, non-steroidal anti-inflammatory medications, wrist
splinting, steroid injections and a combination of both
wrist splinting and steroid injections. This patient was
diagnosed with corticosteroid-induced hypopigmentation secondary to her recent injection. Proper
anticipatory guidance was provided and the patient was
reassured that her normal pigment should return with
discontinuation of steroids. The patient was scheduled to
follow up in four months for re-evaluation of her wrist.

DISCUSSION
Pigmentation of skin is dependent upon the amount and
function of melanocytes. Skin hypopigmentation results
from either a decreased number of melanocytes or an
injury to the melanocytes' ability to properly transport
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melanin to the skin surface. It is hypothesized that steroids
likely interfere with melanin synthesis within melanocytes,
causing an area of hypopigmentation that is reversible
with discontinuation of steroids.8
Localized corticosteroid injections are a well-established
and effective therapeutic intervention for inflammatory,
crystalline, and mechanical arthropathies. In a pooled
meta-analysis, injection alone was shown to have a higher
cure rate than any other therapeutic avenue, with a
reported 83% cure rate.9 Complications can arise from
the process of the injection itself, including local trauma
and infection, and those due to the effect of a locally
injected steroid, such as post injection flare where there
is a local inflammatory reaction that appears and resolves
within 24-48 hours after injection, and late skin changes
such as atrophy and depigmentation.1 Depigmentation
has been shown to be more likely to occur in dark-skinned
individuals and arises between 1-4 months after injection.
Time to resolution of hypopigmentation is variable,
reportedly taking anywhere between 6-30 months to
return to baseline.10,11 This complication is widely described
in the literature. However, it is relatively rare, with an
incidence of less <1% of all injection.

KEY POINTS
Hypopigmentation is a well-known complication of
steroid injections. Though infrequently encountered and
relatively benign, it remains an important complication to
explain to patients prior to the procedure.
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Death by Delirium: A 71-Year-Old Male with
Poor Post-operative Recovery
William Bradford, MD

INTRODUCTION
Delirium is an acute decline in attention and cognition
not better explained by another medical condition.1 It is
multifactorial in origin, with risk factors including advanced
age, male sex, baseline decreased cognitive status,
sensory impairment, poor baseline functional status,
polypharmacy, and multiple comorbid conditions. Acute
precipitants for delirium include administration of
psychoactive medications (particularly benzodiazepines,
narcotics, anticholinergic medications, and general
anesthesia), sleep deprivation, major surgery, and new
illness or worsening of current illness.1 Delirium accounts
for some 49% of all hospital days in older patients,
increases rates of mortality and morbidity, and is
associated with lasting cognitive impairment after
discharge, even in younger patients.2

CASE PRESENTATION
Mr. M was a 71-year-old male Vietnam-War veteran living
independently and working as a standardized patient at a
local medical college. The patient had a past medical
history of cirrhosis due to nonalcoholic steatohepatitis
(NASH), multiple sclerosis (MS), atrial fibrillation (AF), and
diverticulosis. He presented as a transfer from an outside
hospital for management of decompensated NASH
cirrhosis precipitated by a mechanical fall, resulting in a
right hip replacement eleven days prior. He was admitted
to an inpatient hepatology service and shortly after
admission, he was noted to have altered mental status.
Admission blood cultures were positive for Klebsiella
pneumoniae and purulent drainage was noted from the
hip incision. The patient was taken to the operating room
by orthopedic surgery for hip replacement washout and
revision and transferred to the surgical intensive care unit
(SICU) postoperatively for hypoxic respiratory failure
requiring intubation. After an 8 day course in the SICU
marked by persistent delirium, the patient was transferred
back to the hepatology service for further management.
On arrival to the hepatology service, Mr. M had moderate
global weakness, severe dysphagia requiring tube feeds
via a dobhoff tube (DHT), and recurrent bouts of
symptomatic AF with rapid ventricular response. The
patient was maintained on ciprofloxacin for suppression
of his prosthetic joint infection. His course over the
ensuing days was marked by episodes of disorientation,

vivid visual and auditory hallucinations, and alternating
somnolence and agitation. His hospital course was further
complicated by bilateral lower extremity deep vein
thromboses, persistent severe dysphagia, post-traumatic
stress disorder with flashbacks, periodic mild
hypernatremia, and poor tolerance of physical therapy.
He had worsening of his hallucinations, inability to follow
commands, and decreased orientation after an EGD for
banding of esophageal varices. These symptoms
improved slightly after his home baclofen (for multiple
sclerosis) was tapered and ceftriaxone was substituted for
ciprofloxacin. Head magnetic resonance (MR) imaging,
MR angiography and multiple computed tomography
(CT) scans showed no evidence of an acute intracranial
process or major worsening of his known MS lesions. His
blood urea nitrogen (BUN) was within normal limits, and
he was maintained on lactulose and rifaximin with stool
output at or above goal 3-4/day throughout his stay. On
hospital day 53, 39 days after his transfer from the SICU
to the floor, he developed lactic acidosis, severe acute
kidney injury, and became acutely hypoxic with increased
work of breathing. He was offered intubation and further
workup for his severe sepsis; however, his decision-maker
opted for hospice.

DIFFERENTIAL DIAGNOSIS
Mr. M suffered discrete episodes of altered mental status
that were precipitated by anesthesia, sleep deprivation
due to late lab draws, nighttime administration of
ciprofloxacin and baclofen, and known triggers of his
post-traumatic stress disorder (including hospital
helicopter landings and thirst). These episodes decreased
in frequency with adequate sleep, reorientation measures,
control of his thirst, use of atypical antipsychotics, and
removal of a fecal management system. His ammonia
was elevated initially at 49, at which point he was
empirically started on lactulose and rifaximin with stool
output at or above goal. He was euglycemic throughout
his stay. The patient had no kidney disease or elevated
BUN to suggest uremia. Exhaustive brain imaging did not
re v e a l a n y s i g n i f i c a n t i n t r a c r a n i a l p a t h o l o g y.
Comprehensive infectious workup found no new
infection or recurrence of his previous joint infection.
Given his critical illness, waxing and waning mental status,
and lack of improvement despite correction of other
identifiable causes, the diagnosis of delirium was made.
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OUTCOME AND FOLLOW-UP
The patient expired two days after transfer to inpatient
hospice.

DISCUSSION
Mr. M’s unfortunate case illustrates prolonged delirium
leading to a cascade of complications that ultimately led
to what was likely a hospital-acquired infection resulting
in his death. This case highlights the importance of early
recognition and aggressive treatment of delirium in
hospitalized elderly patients. Although Mr. M predominantly
displayed hyperactive delirium, it is estimated that some
75% of delirium cases are the more insidious hypoactive
form, which is associated with worse outcomes, possibly
because it more often goes undiagnosed and untreated.3
As the front-line provider for inpatients, the resident
physician is able to have a major impact on the recognition
and treatment of delirium.
Recognition of delirium begins with clinical suspicion
based on risk factors. A bedside diagnostic test, such as
the Confusion Assessment Method (Figure 1A), should
follow.1 If the diagnosis of delirium is confirmed, the
clinician should perform a thorough evaluation for the
underlying cause. The DELIRIUM mnemonic provides a
useful approach for this evaluation (Figure 1B). 1 The
cornerstone of delirium management is well-integrated
care by all members of the healthcare team as well as the
patient’s family to identify and address all modifiable
contributors. Physical restraints, although frequently
utilized, are actually associated with increased risk of

Figure 1A: The Confusion Assessment Method
for diagnosing delirium
To diagnose delirium, features 1 and 2 and either 3 or 4 are required
1. Acute change in mental status with a fluctuating course
2. Inattention
3. Disorganized thinking
4. Altered level of consciousness

Figure 1B: The DELIRIUM mnemonic for
underlying causes of delirium
Drugs
Electrolyte disturbances
Lack of drugs
Infection
Reduced sensory input
Intracranial etiologies
Urinary and fecal disorders
Myocardial and pulmonary disorderss
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injury and persistence of delirium after discharge.4 Their
use should be reduced or eliminated on the general
wards but may be necessary in the ICU to prevent
dislodgement of lines and tubes. Use of a sitter should be
considered in lieu of restraints. Pharmacologic treatment
with antipsychotics may be required for patients with
distressing perceptual disturbances or delusional thoughts
but should not be employed without attention to potential
underlying reversible causes.
Prevention is the best approach to delirium, with the key
components of the prevention strategy established in a
1999 study which showed that reorientation, non-pharmacologic sleep protocol, getting the patient out of bed,
encouraging the use of glasses/hearing aids, and
encouraging fluid intake result in lower rates of delirium
in hospitalized elderly.5 Some studies also show benefits
for elderly patients who receive geriatric consultation
early in their hospital stay. More aggressive prevention,
especially closer attention to hydration status and more
attention to preventing nocturnal awakenings early in his
stay, might have prevented such a tragic outcome for Mr.
M and other patients like him.

KEY POINTS
• Delirium, especially the hypoactive form, is an underrecognized and preventable complication of hospitalization in elderly patients.
• Advanced age, male sex, baseline cognitive impairment,
polypharmacy, and multiple comorbidities are risk
factors for development of delirium.
• Reorientation, institution of a non-pharmacologic
sleep protocol, getting the patient out of bed,
encouraging the use of glasses/hearing aids, and
encouraging fluid intake result in lower rates of delirium
in hospitalized elderly.
• Antipsychotic medications should only be used when
necessary to prevent harm to the patient and should
be initiated at a very low dose (0.25 mg IV is the
recommended starting dose of haloperidol).
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A Case of Secondary Hemophagocytic
Lymphohistiocytosis in an Adult Patient Treated
with Concurrent Dexamethasone and
Interleukin-1 Receptor Blockade
Vikas Sunder, MD

INTRODUCTION
Hemophagocytic Lymphohistiocytosis (HLH) is a rare,
life-threatening syndrome of overwhelming inflammation
caused by activation and proliferation of T-lymphocytes
and hemophagocytic macrophages.1 This uncontrolled
proliferation of macrophages creates a cytokine storm
with resultant tissue damage. HLH is associated with
clinical and laboratory findings which include fever,
cytopenias, hepatic dysfunction, splenomegaly, and
marked hyperferritinemia. 1-3 There exists limited
epidemiologic data on adult (age ≥ 18 years) cases of
HLH, and its incidence is uncertain.2,4 HLH can be due to
inherited mutations causing immune system
dysregulation or secondary to underlying malignancy,
infection, or rheumatologic condition. Macrophage
activation syndrome (MAS) refers to HLH that occurs
secondary to rheumatologic diseases.5 Approximately 8%
of HLH cases in adults occur secondary to rheumatologic
diseases.4 The overall 30-day mortality for HLH in adult
patients is approximately 44% and can be related to the
underlying trigger with malignancy-associated HLH
patients having a higher mortality.4 A key barrier to HLH
treatment in adults is delay in diagnosis given the lack of
specific laboratory findings to distinguish it from bacterial
sepsis.1,2 The treatment for HLH in adults, beyond early
initiation of steroids, remains unclear given its rarity, with
much of our understanding of HLH derived from the
pediatric literature.5

Figure 1. Erythematous rash involving the back.

Physical exam was significant for conjunctival injection
and icterus, tachycardia, and blanching erythematous
patches involving the chest, upper arms and back
(Figure 1). The patient’s admission labs were notable for
hyperbilirubinemia, transaminitis, thrombocytopenia,
and leukopenia with significant bandemia (Table 1).

Table 1: Labs for Admission to the hospital
Lab

Result

Lab

Result

CASE PRESENTATION

Hemoglobin (g/dL)

13.2 L

AST (IU/L)

480 H

A 26-year-old man presented to an outside Emergency
Department (ED) with 3 days of fevers to 103°F, headache,
and rash on his upper chest and upper extremities. He was
discharged home with ibuprofen, but represented to the
ED when his fevers did not resolve. The patient had a
history notable for Raynaud’s syndrome diagnosed as a
toddler. Five months prior to admission, he was hospitalized
for a pyogenic hepatic abscess for which he underwent
percutaneous drainage and a 6-week course of ciprofloxacin
and metronidazole. His only complaint was vague right
upper abdominal soreness. Vital signs were notable for
heart rate of 115 beats/minute and fever to 102.2°F.

WBC (B/L)

2.8 with 66%
bands L

ALT (IU/L)

591 H

Platelets (B/L)

86 L

Total Bilirubin
(mg/dL)

3.9 H

BUN (mg/dL)

8

Albumin (g/dL)

3.9

0.9

ANA titer

>1:640 H

Ferritin (ng/mL)

6881 H

Anti-RNP/SM
ELISA (U/mL)

>1562 H

LDH (IU/L)

1064 H

CRP (mg/dL)

12.1 H

Creatinine (mg/dL)
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Table 2: HLH-2004 Criteria for Hemophagocytic
Lymphohistiocytosis Observed in Case
HLH-2004 Diagnostic Criteria

Patient

Fever>38.5 °C

*Temperature 39.2 °C on admission

Splenomegaly

*Present on multiple imaging
modalities abdominal ultrasound,
CT scan of abdomen

Cytopenia with 2 of following:
hemoglobin <9 g/dL,
Platelets <100 (B/L), absolute
neutrophil count <1000

ANC 2548 on admission, platelet
count 81 (B/L)

Hypertriglyceridemia
and/or hypofibrinogenemia

Fibrinogen 257 mg/dL, Triglycerides
144 mg/dL (Within normal limits)

Hemophagocytosis in
bone marrow, spleen,
lymph node or liver

*Bone marrow biopsy with increased
number of macrophages with
hemophagocytic activity

Low or absent
Natural Killer cell activity

Flow Cytometry with NK cells making
up 6% of lymphocyte lineage

Ferritin>500 ng/mL

*6881 ng/mL

Elevated soluble CD25 (IL-2)
receptor (U/mL)

*3304 U/mL

DIFFERENTIAL DIAGNOSIS
Sepsis was at the top of the differential so the patient was
started on broad spectrum antibiotics with daptomycin,
aztreonam, and doxycycline to cover for arthropodborne infection given the high fevers and rash. A
computed tomography (CT) scan of the abdomen/pelvis
with contrast was performed and showed scarring at the
site of the previous hepatic abscess and splenomegaly.
The absence of a new hepatic abscess on imaging, along
with the patient’s upward trending fever curve over the
next 2 days while on broad spectrum antibiotics moved
the suspected diagnosis towards a non-infectious cause
of severe inflammatory disease. The patient’s ferritin level
dramatically increased from 6,800ng/mL on admission to
10,000ng/mL on day 3. The antinuclear antibody (ANA)
titer resulted as >1:640, and Anti-RNP/Sm ELISA was
>1562U/mL, concerning for an underlying autoimmune
condition. A soluble serum interleukin-2 (IL-2) receptor
level was elevated to 3,300U/mL. A bone marrow biopsy
showed an increased level of macrophages, some of
which contained phagocytized cells. Given the composite
of this primary data, along with worsening clinical status,
HLH-2004 diagnostic criteria was applied and unified this
patient’s clinical syndrome as HLH based on meeting five
of the eight criteria (Table 2).
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OUTCOME AND FOLLOW-UP
Treatment with IV dexamethasone was initiated on day 3
of admission for a suspicion of HLH. Intravenous
Immunoglobulin (IVIG) 1g/kg/day for two doses and
anakinra 100mg twice daily were also initiated on day 4 of
admission given the lab-work suggesting an underlying
rheumatologic trigger. Etoposide, a recommended
treatment for non-rheumatologic HLH, was not given
due to this patient’s extensive hepatic disease,
pancytopenia, and likely rheumatologic trigger. 6 The
patient’s fever curve, ferritin level, and transaminases
down-trended, and his rash greatly improved over the
next few days. Dexamethasone was stopped 30 days
after discharge based on improving lab-work and the
anakinra is to be continued indefinitely with rheumatology
follow-up. 60 days after initial admission, the patient’s
ferritin level normalized, and he returned to his baseline
functional independence.

DISCUSSION
HLH is a life-threatening disease marked by severe
uncontrolled inflammation. HLH in adults remains an
elusive diagnosis given its non-specific laboratory findings.
Studies have shown that marked hyper-ferritinemia
>50,000µg/L is not predictive of HLH in adult populations,
as opposed to pediatric populations in which it is 90%
sensitive and 98% specific. 7 The major obstacle to
initiating HLH treatment is a delay in diagnosis as was
evident in our case. In our patient, the soluble IL-2
receptor level, which reflects the activation of T-cells, was
highly elevated in accordance with cytokine mediated
organ dysfunction associated with HLH. 2,5 There is,
however, a time delay in obtaining the IL-2 receptor level,
which may take 3- 6 days to result. Overall, our patient’s
presentation was in line with documented cases of adult
HLH in that our patient had a fever (93% of cases),
splenomegaly (50% of cases), elevated ferritin (98% of
cases), and hemophagocytosis seen on bone marrow
biopsy (97% of cases).4,8-11 Given that diagnosis remains a
barrier to HLH treatment, future work should focus on
developing adult specific diagnostic criteria. In 2014, a
research group based in Paris constructed a diagnostic
score called the “HScore” which may be used to estimate
an individual’s risk for reactive hemophagocytic syndrome
according to weighted criteria. This tool is freely available
online, but it has limitations including non-specific cutoff
values for the criteria and it requires further validation in
prospective study.12
The principle of HLH management is to suppress the
unregulated inflammation. 2 There is a more specific
HLH-2004 treatment protocol which comes from
pediatric literature and includes an initial 8-week course of
chemo-immunotherapy with etoposide, dexamethasone,
and cyclosporine A upfront for patients who are less than

18 years of age and meet HLH-2004 diagnostic criteria.6
Early initiation of dexamethasone, which can cross the
blood brain barrier, appears to be of benefit in documented
adult cases of HLH and was in this case.2 Treatment of the
underlying trigger can often lead to control or resolution
of the secondary HLH. Our patient had an unclear but
likely rheumatologic trigger and was treated with anakinra,
an IL-1 receptor antagonist. The exact role of IL-1 in HLH
is unknown, but considering the end-product of HLH is an
increased production of cytokines, it would make sense to
see IL-1 up-regulation. 1 Anakinra has been used with
positive response in patients with HLH secondary to
Systemic Juvenile Idiopathic Arthritis, Adult Still’s disease,
Systemic Lupus Erythematosus, and even Cytomegalovirus
infection.1,3,8,9,11 It is clear that not all adult cases of HLH
require initiation of the complete HLH-2004 protocol
treatment, which includes chemotherapeutics, as these
medications carry harmful side effects.2 Use of a biological
response modifier along with dexamethasone may
achieve treatment of secondary HLH in an adult patient as
exemplified by this case. Further reporting of successful
treatment regimens is crucial to developing trigger specific
HLH treatment protocols, given that these patients carry
different prognoses based on their underlying cause.4
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Resistant Raoultella Ornithinolytica Bacteremia
in a Patient with New Acute Myeloid Leukemia
Mario Caldararo, MD

INTRODUCTION
Members of the Raoultella genus were formerly considered
to be Klebsiella species until they were differentiated based
on phylogenetic Deoxyribonucleic acid (DNA) analysis.1
Since then, Raoultella ornithinolytica has been sparsely
implicated in clinically-apparent disease, though more
case reports are appearing as of late. Here we report the
first documented instance of R. ornithinolytica bacteremia
in a patient with new acute myeloid leukemia (AML).

CASE PRESENTATION
A 71-year-old man was transferred to our hospital for
treatment of newly discovered AML. Prior to transfer, he
experienced an aching abdominal pain attributed to
pancreatitis and daily episodes of watery diarrhea for
five days.
On admission, he had an oral temperature of 102.7°F,
pulse of 96 beats per minute, blood pressure of 145/70
mmHg, and oxygen saturation of 97% on room air.
Physical exam revealed gray-brown granular material
along the gum line of the third tooth that was tender to
palpation, tender lymphadenopathy in the right
submandibular space and right anterior cervical chain, a
grade 2/6 systolic murmur, and no peripheral edema.
Abdominal exam revealed tenderness and guarding over
the left upper quadrant and epigastrium. The remainder
of the physical exam was unremarkable.
Lab work revealed a white blood cell (WBC) count of 25.0
x 109/L with 52% blasts, hemoglobin of 7.4 g/dL, and
platelets of 36,000 x 109/L. Lipase, liver enzymes, and
creatinine were within normal limits. There was no
acid-base derangement. Nucleic acid amplification
testing for Clostridium difficile toxin was negative.
Since initial imaging was not available, a computed
tomography (CT) scan of the abdomen without contrast
was performed showing duodenitis—but not pancreatitis.
Further diagnostic workup was deferred to expedite the
initiation of chemotherapy for the patient’s concomitant
AML. Ten days of empiric therapy for Helicobacter pylori
was completed with clarithromycin 500 mg PO every 12
hours, amoxicillin 1 g PO every 12 hours, and pantoprazole
40 g PO daily.
Hydroxyurea was administered due to a steadily increasing
WBC count which peaked at 36.4 x 109/L. The patient
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remained febrile during this time and was considered
functionally neutropenic due to his malignancy, therefore
was treated for neutropenic fever with piperacillintazobactam 3.375 g IV every 6 hours.
On day 6 of his hospitalization, induction chemotherapy
was begun with a "7+3" regimen of idarubicin and
cytarabine. From approximately day 8 to day 35 of his
hospitalization, he remained neutropenic with an absolute
neutrophil counts (ANC) in the 0.2-0.3 x 109/L range and
his piperacillin-tazobactam was continued. His abdominal
pain and diarrhea persisted over this time.
On day 14, the patient's fever curves shifted from
100-101 °F to 101-103°F. On day 16, a CT scan of the
abdomen with contrast was again performed, showing
evidence of ongoing duodenitis without additional
pathology. Blood cultures were redrawn on days 15, 16,
and 17 and were all negative.
On day 19, FilmArray Blood Culture Identification Panel by
BioFireDx identified the family Enterobacteriaceae from
cultures taken that same day and while the patient was
still on piperacillin-tazobactam. The test was negative for
Enterobacteriaceae cloacae complex, Escherichia coli,
Klebsiella oxytoca, Klebsiella pneumoniae, Proteus, and
Serratia marcescens; this is the extent of the genera of
Enterobacteriaceae included in this particular test.
Overnight on day 20, the patient vomited and aspirated in
his sleep, developing acute hypoxia to SpO2 of 74% on
room air, respiratory rate of 34 breaths per minute, and
pulse of 133 beats per minute. A portable chest x-ray
showed a possible consolidation in the right lower lobe.
Due to the patient's extended hospital stay and immunocompromised status, vancomycin was added and
piperacillin-tazobactam was changed to meropenem.
On day 21, a lactose-fermenting gram-negative rod was
identified from the blood culture obtained two days prior.
Our lab reported that this most closely resembled
Raoultella ornithinolytica. Antibiotic susceptibility patterns
were remarkable for resistance to piperacillin-tazobactam
with MIC >64/4 mcg/mL. The organism was susceptible
to amikacin and meropenem (Table 1).
A single 15 mg/kg dose of amikacin was administered.
Surveillance blood cultures from days 21-26 were negative
for further gram-negative infection. On day 24, a CT scan
of the abdomen with contrast was repeated showing

obstruction despite ongoing diarrhea, thickened and
inflamed segments of jejunum, and persisting duodenitis.
On day 25, the patient was started on bowel rest, and
total parenteral nutrition (TPN) was initiated.
Anidulafungin was administered from days 18-29 for
concern of indolent fungal infection. The patient became
delirious for the remainder of his hospital course. He
received treatment with granulocyte colony stimulating
factor to help bolster his leukocyte counts. The patient
did not defervesce until day 35, at which point his mental
status also improved. On day 37, his ANC surpassed 0.5 x
109/L. On day 38, meropenem was stopped; TPN was
also discontinued as the patient began tolerating an oral
diet. He had no further positive blood cultures. On day
40, a repeat chest x-ray demonstrated improvement of
his right lower lobe and he was deemed medically stable
for discharge to a rehabilitation facility.

DISCUSSION
A case series and literature review of R. ornithinolytica
infections from four university hospitals in France found
bacteremia to occur only in 5% of cases.2 In the setting of
malignancies, there is a 16-patient case series in which 15
had recent underlying malignancies both solid and
hematologic,3 a three-patient case series of bacteremia
with underlying gastric and biliary malignancies,4 and a
report of a patient with acute lymphocytic leukemia (ALL)
who died of R. ornithinolytica sepsis.5 The literature thus
indicates that R. ornithinolytica bacteremia tends to
occur in patients with active comorbidities, especially
malignancies, as in our patient.
Among more resistant R. ornithinolytica isolates, a
blood culture isolate in New Jersey was susceptible
only to amikacin and gentamicin, 6 a blood culture
isolate in Brazil was susceptible only to amikacin,
gentamicin, ciprofloxacin, and levofloxacin,5 and other
carbapenemase-producing strains were found in China7
and Turkey.8 R. ornithinolytica has natural susceptibility
to cephalosporins, carbapenems, aminoglycosides;
intermediate susceptibility to some penicillins, not
usually including piperacillin/tazobactam; and resistance
to macrolides.9
R. ornithinolytica is susceptible to piperacillin-tazobactam
a majority of the time.2-4, 7, 10-11 This case highlights the
importance of antibiotic stewardship to prevent the
inducible resistance that likely contributed to the failure of
piperacillin-tazobactam in this case. Febrile neutropenia
presents an especially difficult challenge as these patient
scenarios often necessitate very long courses of very
broad antibiotics in the absence of identified organisms.
Procalcitonin may be of potential value in guiding
antibiotic administration in patients with febrile
neutropenia. Some data indicate that procalcitonin may
be useful in distinguishing infectious from non-infectious

etiologies of neutropenic fever, as well as trending values
to monitor for response to therapy.12-14
This case also emphasizes the importance of rapid
diagnostics. The assay used in this case used multiplex
polymerase chain reaction (PCR) technology to identify
an organism belonging to the family Enterobacteriaceae
that was specifically not a member of the Klebsiella genus
or other genera within Enterobacteriaceae. This particular
pattern should evoke concern for Raoultella, a former
member of the Klebsiella genus which should be
considered as virulent and resistance-prone as
Pseudomonas. By quickly identifying a new organism,
which persisted through piperacillin-tazobactam therapy,
the assay prompted the switch to meropenem and
prevented the patient from succumbing to his bacteremia.
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Abdomen Actin’ Up: A Unique Presentation
of Disseminated Abdominal Actinomycosis
Arpana Paruchuri, MD, Brianna J. Shinn, MD, and Rino Sato, MD

INTRODUCTION
Abdominal actinomycosis is a chronic, indolent disease
characterized by nonspecific symptoms such as fatigue,
weight loss, fever, and abdominal pain. Actinomyces is a
genus of fastidious, gram-positive, non-acid-fast,
branching filamentous bacilli characterized by sulfur
granules that is normally found in oral flora and inhabits
the gastrointestinal (GI) tract.1 Actinomyces infections are
relatively rare, however when present, they have the
ability to invade multiple organs and disseminate
throughout multiple body cavities.2 Factors that increase
the risk of developing actinomycosis include poor oral
hygiene, alcoholism, and preexisting dental disease.
Intrauterine devices (IUDs) also increase the risk of
developing pelvic actinomycosis.3 Over the past 10-20
years, actinomycosis is being diagnosed with increasing
frequency and should be considered in the differential for
patients presenting with indolent abdominal symptoms
along with risk factors.4

Figure 2. Actinomyces meyeri from the patient’s abdominal wall abscess.

On exam, he was afebrile, had a blood pressure of 85/70
mmHg, and an oxygen saturation of 84% on room air.
The patient had poor dentition, decreased breath sounds
bilaterally, and multiple abdominal masses palpable in the
left lower quadrant and along the liver border. Labs were
remarkable for an elevated lactate of 2.3 mmol/L,
hemoglobin of 7.6 g/dL, and albumin level of 1.9 g/dL. His
white blood cell (WBC) count and arterial blood gas were
within normal limits. Imaging revealed a large right-sided
pleural effusion with septations and complete collapse of
the right lung (Figure 1), as well as multiple intra-abdominal
abscesses with air-fluid levels.

Figure 1. CT Chest demonstrating right-sided pleural effusion with complete
collapse of the right lung.

CASE PRESENTATION
A 57-year old male with a history of untreated hepatitis C,
treated tuberculosis (TB), and recent incarceration
presented to the emergency room with abdominal pain,
shortness of breath and weight loss. Of note, he had
undergone a liver biopsy two weeks prior to presentation
to further evaluate a liver lesion that showed acute
and chronic inflammation without evidence of
malignancy or infection.
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DIFFERENTIAL DIAGNOSIS
Due to his history of previously treated TB, recent
incarceration, and recent liver biopsy, the source of
infection was thought to be due to TB or a bacterial
source introduced from his recent liver biopsy. Given the
imaging findings which demonstrated a pleural effusion
with septations, the patient had a surgical chest tube
placed which drained over three liters of purulent fluid.
Based on Light’s criteria the pleural fluid was classified as
an exudative effusion, with 16,075 WBCs/mm3, Glucose
< 2.0 mg/dL, LDH of 4110 IU/L, and a pH of 7.0. Based
on these results and the presence of pus in the pleural
space, he was diagnosed with an empyema.

OUTCOME AND FOLLOW-UP
After the patient’s surgical chest tube was placed, he
underwent drainage of the abdominal wall abscesses.
Cultures from both the pleural fluid and abdominal
abscess fluid grew Actinomyces meyeri and the patient
was diagnosed with disseminated actinomycosis (Figure
2). The patient ultimately required a video-assisted
thoracoscopic surgery (VATS) and decortication during
which time he was noted to have a fistulous connection
between a hepatic abscess and the right hemithorax.
Since the patient’s poor dentition was presumed to be the
initial source of this infection, he also underwent tooth
extraction. He was treated with intravenous Unasyn for six
months without transition to oral Penicillin given his
complicated presentation. Unasyn was chosen due on its
broader coverage and its ability to treat any concomitant
infections in this complicated patient. Repeat imaging of
his abdomen 2 months after his presentation showed a
decrease in size of his intra-abdominal collections.

DISCUSSION
Abdominal actinomycosis is an infection in the abdomen
most commonly caused by Actinomyces israelii, which is
normally an inhabitant of the oral cavity and GI tract.1
Actinomyces meyeri, while a less common cause of
abdominal actinomycosis, has a greater propensity for
causing disseminated disease.3 Although Actinomyces
normally has low virulence, it acquires its pathogenicity
through invasion of necrotic tissue or local infections or
trauma. As the infection progresses, granulomatous
tissue, extensive reactive fibrosis and necrosis, abscesses,
draining sinuses, and fistulas can be seen. The most
frequent sites of infection include the cervicofacial
region (50% of cases), abdominal cavity (20%), and
thoracic cavity (15-20%). 2 Patients with abdominal
actinomycosis, including our patient, generally present
with a chronic, indolent course of nonspecific symptoms
such as fatigue, fever, weight loss, and abdominal pain.
Physical exam findings may include a palpable
abdominal mass, visible sinus tracts, or fistulas and labs
can demonstrate anemia and leukocytosis.5 Culturing
abscess fluid is the most effective way to diagnosis an
Actinomyces infection. Once diagnosed, the treatment
of choice is IV Penicillin G for 4-6 weeks followed by
Amoxicillin for 6-12 months for large abdominal lesions
or draining sinus tracts.2

pleural space was thought to be due to local trauma and
direct seeding from the liver biopsy. However, there are
cases reports in the literature that describe fistula
development between different body cavities allowing
for disseminated disease.3 While fistula development is
rare, it is an important complication to be aware of since
disseminated disease can be difficult to control and treat.
While abdominal actinomycosis is a relatively rare
condition, this case is significant given the rising incidence
of this disease over the past 10-20 years. It is important
for physicians to be educated about this disease especially
given its vague and non-specific symptoms so that it can
be included in the differential diagnoses for patients
presenting with an insidious onset of abdominal
symptoms as well as predisposing risk factors.

KEY POINTS
• While still rare, the incidence of abdominal
actinomycosis is increasing.
• Abdominal actinomycosis presents with a chronic,
indolent course of nonspecific symptoms similar to
other, more common conditions and, should be
considered in patients with indolent abdominal
symptoms and risk factors including poor dental
hygiene, dental disease, and alcoholism.
• The diagnosis is based on abscess fluid culture growing
Actinomyces.
• Treatment of actinomycosis is generally with a long
course of IV Penicillin G later transitioned to oral
Amoxicillin.
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Abdominal actinomycosis is a difficult condition to
diagnose due to its rarity, nonspecific symptoms, and its
resemblance of more common conditions such as
malignancy, Crohn’s disease, and tuberculosis.2 Our
patient’s case was further complicated by the fact that
the infection invaded the thoracic cavity and led to
development of an empyema and disseminated
actinomycosis. In our patient’s case, this invasion of the
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Tenofovir Cons the Kidneys:
A Case of Acquired Fanconi
Ritu Nahar, MD and Emma Lundsmith, MD

INTRODUCTION
Proximal (Type 2) renal tubular acidosis (RTA) is a relatively
rare diagnosis, especially in adults. It is characterized by a
reduction in proximal bicarbonate reabsorption resulting
in urinary bicarbonate wasting. Proximal RTA can also be
associated with additional defects in proximal tubular
function including impaired reabsorption of phosphate,
glucose, uric acid, and amino acids. Generalized proximal
tubular dysfunction is termed Fanconi syndrome. While
there are primary causes of Fanconi syndrome including
sporadic and familial sources, this syndrome can also be
acquired. Two major culprits include monoclonal
gammopathies resulting in increased excretion of
immunoglobulin light chains and drug-induced nephrotoxicity to the proximal tubules.1 Tenofovir disoproxil
fumarate (TDF) is one such established nephrotoxic
agent associated with Fanconi syndrome, likely because
it is excreted through the kidney via active tubular
secretion.2-4 This case demonstrates a classic presentation
of tenofovir-induced Fanconi syndrome complicated by
respiratory repercussions of hypophosphatemia, and
also describes tenofovir alafenamide (TAF), a novel
formulation with reduced renal toxicity.

CASE PRESENTATION
A 63-year-old male and active smoker with human
immunodeficiency virus (HIV) on Atripla (efavirenz/
emtricitabine/TDF), intermittent alcohol abuse for
years, severe chronic obstructive pulmonary disease
(COPD) on no home oxygen presented with three
months of progressive dyspnea on exertion with
ambulatory dysfunction. The patient endorsed dyspnea
after ambulating 5-10 feet, with associated diffuse body
weakness. He noted frequent falls requiring use of a
walker. Over the six weeks prior to presentation, he had
been treated multiple times for presumed COPD
exacerbations with attempts to optimize his triple
inhaler therapy. He noted minimal improvement in his
respiratory symptoms despite these interventions.
Three months prior to presentation, he had been
functionally independent.
He was diagnosed with HIV 20 years prior, and had
achieved virologic suppression on Atripla without any side
effects. His history was also significant for coronary artery
disease with non-ST-elevation myocardial infarction in
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2012, prior stroke of the corona radiata in 2012,
hypertension, and Barrett’s esophagus. He endorsed
increased alcohol consumption in the last few months
to three drinks daily. He was an active smoker using
about half a pack of cigarettes per day. He denied
recreational drug use.
He reported no history of fever, chills, diarrhea, recent
travel, cough, sputum production, chest pain, lower
extremity swelling, orthopnea, or paroxysmal nocturnal
dyspnea.
On admission, the patient had a blood pressure of 110/70
mmHg with negative orthostatics, oxygen saturation of
96% on room air at rest but 79% with ambulation. He
subsequently developed hypoxia at rest as well. On
exam, the patient had diffusely decreased breath sounds
with no appreciable wheezes, crackles, or rales. He had
a regular S1 and S2 with no jugular venous distension or
peripheral edema. Neurological exam was grossly
unremarkable with 5/5 strength in all extremities and
intact sensation.
Labs were significant for serum bicarbonate 16 meq/L,
lactate 2.5 mmol/L, magnesium 0.8 mg/dL, phosphate
0.8 mg/dL, albumin 3.6 mg/dL, hemoglobin 8.3 g/dL,
CD4 173 with undetectable viral load. Urinalysis revealed
3+ glucose and pH 7.0. Urine phosphate 27 mg/dL and
creatinine 43 mg/dL.
Transthoracic echocardiogram demonstrated an
ejection fraction of 70% with normal left ventricular size
and function. Chest x-ray had no focal consolidation or
edema. Computed tomography (CT) angiography of the
chest was negative for acute pulmonary embolism.
Non-contrast CT head demonstrated no intracranial
hemorrhage, masses, or lesions.

DIFFERENTIAL DIAGNOSIS
This patient’s constellation of symptoms including
progressive shortness of breath, ambulatory dysfunction,
normal anion gap metabolic acidosis with hypophosphatemia and hypomagnesemia was initially challenging
to unify under one diagnosis.
His primary complaint of progressive shortness of breath
had a broad differential. Given his COPD history and
new oxygen requirement, progression of his underlying

disease was considered. The timeline of his symptoms
and objective physical exam did not support an acute
exacerbation. CT angiogram ruled out pulmonary
embolism. Given his history of coronary artery disease,
heart failure was also considered. However, this was not
corroborated by the patient’s physical exam and the
echocardiogram demonstrated normal ejection fraction.
Thus, we hypothesized that the patient’s progressive
shortness of breath was secondary to hypophosphatemia-induced respiratory muscle fatigue in the
setting of severe COPD.
The differential for the patient’s ambulatory dysfunction
included orthostatic hypotension, ethanol abuse, and a
new mass lesion or stroke given his prior cerebrovascular
history. His neurological exam was unremarkable,
orthostatics were normal, and CT head was unrevealing—
making his falls likely secondary to weakness as opposed
to an intracranial insult. Thus, there may have been a
component of hypophosphatemia-induced muscle
dysfunction.
Normal anion gap metabolic acidosis can be caused by
renal or gastrointestinal loss of bicarbonate, or with
decreased renal acid excretion. Loss of bicarbonate is
seen with Type 2 RTAs, diarrhea, carbonic anhydrase
inhibitors, and toluene inhalation (glue sniffing).5
The patient’s severe hypophosphatemia and hypomagnesemia was initially attributed to malnutrition in the
setting of alcohol abuse. However persistent deficiencies
despite intravenous repletion compounded with the
normal anion gap metabolic acidosis suggested
generalized proximal renal tubular dysfunction.

OUTCOME AND FOLLOW-UP
Fanconi syndrome was eventually suspected and
attributed to TDF. This suspicion was further supported by
a urine pH of 7, 3+ glucosuria, and increased fractional
excretion of filtered phosphate. Atripla (which contains
TDF) was discontinued and the patient was switched to
Descovy (emtricitabine and TAF) and Tivicay (dolutegravir).
The patient's generalized weakness, dyspnea, and hypoxia
improved with normalization of his serum bicarbonate,
phosphate, and magnesium. He was discharged with oral
phosphorus and magnesium supplementation. At his
most recent pulmonary follow-up, he had normal
ambulatory oximetry with increased functionality.

This is thought to be secondary to high circulating plasma
levels of tenofovir which is then excreted through the
kidney via active tubular secretion. Tenofovir alafenamide,
a novel oral prodrug of tenofovir, is metabolized to
tenofovir intracellularly rather than in plasma. This results
in higher intracellular concentrations of the active
metabolite compared to TDF. Consequently, the
therapeutic dose required for TAF is less than one-tenth
of the dose of TDF. 6 The resulting 90% reduction in
plasma tenofovir concentrations is believed to be
responsible for the improved renal safety demonstrated in
several phase 2 and 3 randomized-controlled trials.7 A
recent meta-analysis demonstrated that both
TDF-containing regimens and TAF-containing regimens
have high and comparable rates of virologic suppression.8
While promising, the long-term clinical significance of
TAF still needs to be assessed in prospective cohorts.

KEY POINTS
This case illustrates the renal side effects of TDF-induced
Fanconi syndrome, highlighting the manifestations of
hypophosphatemia. Recognizing this potential side effect
and switching patients to a TAF-containing regimen is
important to prevent renal injury.
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DISCUSSION
Tenofovir disoproxil fumarate, the first approved oral
prodrug of tenofovir, has been successfully used in
combination antiretroviral therapy for HIV treatment since
2001. However, as seen in this case and established in the
literature, TDF can cause clinically significant renal toxicity.
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A Case of Eosinophilic Granulomatosis
with Polyangiitis
Anita Modi, MD and Lily Ackermann, MD

INTRODUCTION
Eosinophilic granulomatosis with polyangiitis (eGPA) is a
small- and medium-sized-vessel vasculitis with multi-organ
manifestations. Given the rarity of eGPA, patients are
often misdiagnosed for decades and may initially present
with life-threatening manifestations of late-stage disease.
Therefore, it is important to raise awareness of this
condition and its associated signs and symptoms. This
case report serves to describe a classic presentation of a
patient with eGPA, as well as to delineate the diagnostic
workup, acute management, and early outpatient
follow-up required.

CASE PRESENTATION
A 57-year-old male with a history of recently-diagnosed
asthma (on chronic prednisone) presented to the
emergency department at our hospital with a month-long
history of shortness of breath and fatigue. He denied
wheezing and chest tightness typical of his asthma flares,
insisting that this isolated dyspnea was similar to the
symptoms he experienced two months earlier when he
presented to an outside hospital and was diagnosed with
symptomatic anemia.
He reported that he was in perfect health until one year
prior to presentation when he developed progressively
worsening respiratory symptoms. After evaluation by a
pulmonologist, he was started on budesonide-formoterol
twice daily in conjunction with his rescue inhaler. However,
he had persistent symptoms over the subsequent six
months, so was ultimately started on prednisone 30 mg
PO daily. At the time, he was noted to have an elevated IgE
and eosinophil count of 104 IU/mL and 900 cells/uL,
respectively. Though he improved dramatically with the
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addition of systemic steroids, he began to develop
generalized fatigue, weakness, chills, night sweats, and
migratory polyarthralgias a couple months later. His
primary care physician suspected Lyme disease and started
doxycycline without symptomatic improvement. He began
taking ibuprofen several times a day for the diffuse joint
pains. As the patient’s shortness of breath and fatigue
worsened, a complete blood count was obtained, and his
hemoglobin was found to be 6 g/dL. He was admitted to
an outside hospital where he received a blood transfusion
and underwent an upper endoscopy and colonoscopy
which did not demonstrate active bleeding. He was
discharged with instructions to avoid further NSAID use.
In the emergency department at our hospital, his
hemoglobin was 7.4 g/dL so he received a blood transfusion
for symptomatic anemia, which was suspected to be due
to an upper gastrointestinal bleed caused by NSAID- and
steroid-induced peptic ulcer disease. His chest x-ray
demonstrated patchy bilateral airspace opacities
throughout both lung fields concerning for multifocal
pneumonia. He was also started on ceftriaxone in
conjunction with his ongoing doxycycline therapy for
treatment of superimposed community-acquired
pneumonia. One hour after receiving one unit of blood,
the patient developed increased work of breathing with
hypoxia that did not improve with diuresis. A computed
tomography (CT) scan of the chest without contrast was
ordered to delineate possible hemorrhage or atypical
infection contributing to his deteriorating presentation. It
demonstrated multifocal airspace opacities in a
peri-bronchial vascular distribution with relative sparing of
the left lower lobe and subpleural spaces, findings
consistent with diffuse alveolar hemorrhage (DAH)” and
noncardiogenic pulmonary edema (Figure 1).

1B
Figure 1. Images from the
patient’s CT scan of the chest
demonstrates multifocal
airspace opacities in a
peri-bronchial vascular
distribution with relative
sparing of the left lower lobe
and subpleural spaces.
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The patient’s systemic symptoms and imaging was
suspicious for an underlying vasculitis complicated by
diffuse alveolar hemorrhage and gastroenteritis. He
underwent bronchoscopy which demonstrated diffuse
bloody secretions in the right upper lobe and lateral
basilar segment of the right lower lobe. Cytology
demonstrated marked acute inflammation with no
evidence of infection. Differential cell count did not
demonstrate eosinophils as would be expected in eGPA,
but this may be related to the patient’s chronic steroid
use pre-procedure. Laboratory studies were significant
for positive C-ANCA and PR-3 antibody with a titer of 4.3.
In conjunction with the patient’s elevated IgE and
eosinophilia from six months earlier, this lab work helped
to confirm the patient’s suspected diagnosis of eGPA.
On further discussion, the patient acknowledged that
he had experienced recurrent sinusitis and exerciseinduced asthma for one decade prior to initial
presentation. His sporadic episodes were managed
by his primary care physician until one year prior
to admission when he sought evaluation by a
pulmonologist and was ultimately started on chronic
prednisone, which alleviated his respiratory symptoms
and likely palliated his underlying vasculitis.

OUTCOME
The patient was pulsed with intravenous methylprednisolone 1 gram daily for 3 days, followed by oral
prednisone 1 mg/kg daily. He also received his first dose
of rituximab with the remaining three weekly infusions
to be scheduled as an outpatient, and two sessions of
inpatient plasmapheresis given his diffuse alveolar
hemorrhage. These interventions resulted in prompt
alleviation of his respiratory symptoms and migratory
polyarthralgias, and he was weaned to room air prior to
discharge. Six months after discharge, his prednisone
has been tapered to 40 mg daily, his repeat CT scan of
the chest demonstrates resolution of focal airspace
opacities initially observed in the setting of DAH, and his
PR-3 antibody titer is negative.

DISCUSSION
eGPA is characterized by the histological findings of
necrotizing vasculitis as well as eosinophilic infiltrates and
granulomas in tissues. 1 The American College of
Rheumatology has since defined six diagnostic criteria, of
which four should be present in a patient with suspected
eGPA: asthma, greater than 10% peripheral eosinophilia,
neuropathy, non-fixed pulmonary infiltrates, paranasal
sinus abnormalities, and extravascular eosinophils. Our
patient had a long history of recurrent sinusitis and asthma
prior to presentation, eosinophilia, and pulmonary
infiltrates. The disease progresses over the course of
decades, classified into three distinct phases: the

prodromal phase that is associated with allergic rhinitis
and asthma; eosinophilic infiltration of multiple organs
including the lungs and gastrointestinal tract; and granulomatosis resulting in life-threatening disease.2
Clinical presentations of eGPA differ based on associated
ANCA positivity. ANCA-negative patients typically present
with more frequent cardiomyopathy, while ANCA-positive
patients present with mononeuritis multiplex and glomerulonephritis. Poorer prognoses can be anticipated for
patients with documented gastrointestinal, renal, or
cardiac manifestations of the disease, meriting screening
endoscopies, urinalyses, and transthoracic echocardiograms of in-patients with newly-diagnosed eGPA. 3
Commonly noted laboratory abnormalities include serum
eosinophilia, elevated IgE levels, and P-ANCA of anti-MPO
specificity. However, up to 40% of patients with eGPA
demonstrate positive C-ANCA of anti-PR-3 specificity.
Extravascular eosinophilia (e.g. in bronchoalveolar lavage
fluid) and biopsy demonstrating granulomas aid in
confirming the diagnosis of eGPA. Despite these objective
features, eGPA is essentially a clinical diagnosis based on
symptom presentation and the presence of eosinophilia.
Recommendations on treatment of eGPA depend on the
severity of disease and organ involvement. Glucocorticoids
are first-line treatment for eGPA and those with severe
documented gastrointestinal, renal, pulmonary, or
cardiac involvement should be prescribed an additional
immunosuppressant (e.g. rituximab, cyclophosphamide).
Though plasma exchange is not merited for every patient
with newly-diagnosed eGPA, it may successfully forestall
progressive glomerulonephritis in ANCA-positive patients
with severe diffuse alveolar hemorrhage and renal
insufficiency.

KEY POINTS
Given the life-threatening complications of this rare
condition, it is important to raise awareness about eGPA.
This is a classic presentation of eGPA in a patient with a
decades-long asthma history, eosinophilia, new lung and
gastrointestinal manifestations, and systemic symptoms.
His serologies were significant for positive C-ANCA of
anti-PR-3 specificity. His clinical course included screening
for gastrointestinal, renal, and cardiac involvement as well
as initiating steroid therapy, plasmapheresis, and rituximab.
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Use of Venovenous Extracorporeal Membranous
Oxygenation Following Iatrogenic Tracheal Rupture
Rajiv Kabadi, MD

INTRODUCTION
Iatrogenic tracheal rupture is a rare complication of
endotracheal intubation and has a high risk of morbidity
and mortality. Risk factors include female gender, short
stature (height less than 160-cm), difficult airway anatomy,
underlying connective tissue disorder, chronic obstructive
pulmonary disease, use of a rigid stylet, inadequate
intubation tube size, cuff over-inflation, emergent
intubation and intubation performed by non-anesthesiologists. 1 Early recognition is important and diagnosis
requires bronchoscopic confirmation.2,3 We describe a
case where emergent venovenous extra-corporeal
membrane oxygenation (VV-ECMO) was utilized in the
management of tracheal rupture.

CASE DESCRIPTION
A 46-year-old female smoker with a history of asthma
presented to an outside hospital with worsening dyspnea
and was found to be in status asthmaticus. She underwent
a difficult intubation on hospital day two for hypercapneic
respiratory failure. She subsequently developed severe
subcutaneous emphysema on her face that spread to her
torso, arms and legs (Figure 1). Computed tomography

of the chest revealed pneumothoraces, pneumomediastinum, pneumopericardium (Figure 2) and pneumoperitoneum (Figure 3). Bilateral chest tubes and a
pericardial drain were placed and she was transferred to
our facility for higher level of care.
Bronchoscopy was performed which revealed a 2-cm
longitudinal laceration in the membranous wall of the
trachea that extended towards the carina. Given these
findings, cardiothoracic surgery was consulted. Due to
refractory hypoxemic and hypercapnic respiratory failure
despite maximal ventilatory support, VV-ECMO was
initiated on hospital day three. Due to improvement in
oxygenation and ventilation, a right thoracotomy with
tracheal repair and pericardial window placement was
performed.
The patient was continued on steroids and bronchodilators for management of her asthma exacerbation.
VV-ECMO was weaned and the patient underwent ECMO
catheter decannulation on hospital day five. She
underwent tracheostomy on hospital day fifteen with
eventual decannulation prior to being discharged to
acute rehab on hospital day thirty-one.

Figure 1. Computed tomographic
(CT) imaging demonstrating extensive
subcutaneous emphysema (A-C),
apical bleb (A), emphysematous
changes in the lungs (B) and bilateral
chest tubes (B; arrows).
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Figure 2. CT imaging demonstrating pneumomediastinum and pneumopericardium (A-B).

permissive hypercapnia for patients with underlying
respiratory disease. Additional measures include daily
bronchoscopic examinations, post-pyloric feeding,
limiting patient movement to specified times, and
antibiotic therapy to reduce risks of mediastinitis and
ventilator-associated pneumonia.4 Surgical intervention
is reserved for patients with uncontrolled air leaks, active
endobronchial hemorrhage, or for patients who have
failed conservative measures as evinced by progressive
ventilator requirements leading to extreme difficulties in
oxygenation and ventilation as was the case for our
patient.1,5 For our patient, VV-ECMO was used as a bridge
to surgical tracheal repair in the setting of status
asthmaticus and respiratory failure. Further studies should
identify patients who will benefit from early surgical
management and/or transfer to an ECMO-ready facility.3

KEY POINTS
• Tracheal rupture is an uncommon but severe
complication of endotracheal intubation.

Figure 3. CT imaging demonstrating pneumoperitoneum (marked by red asterixis).

OUTCOME AND FOLLOW UP
The patient was last seen in the pulmonology clinic 6
months after she was discharged and has maintained
good functional status. She was continued on standard
care treatment for moderate persistent asthma which
was well-controlled despite her continued cigarette
smoking. Her major complaint at the recent office visit
was anxiety rather than cardio-pulmonary symptoms.

DISCUSSION
Tracheal rupture is an uncommon but severe complication
of endotracheal intubation. Conservative management
should be considered for hemodynamically stable
patients without sequela such as progressive air leak,
sepsis, or esophageal injury. Non-operative strategies
involve non-invasive positive-pressure ventilation for
patients who are breathing spontaneously, or
endotracheal intubation and fixation distal to the rupture
site (“bridging”) with low-tidal volume ventilation and

• VV ECMO may be used as a bridge to definitive
management of tracheal rupture in patients with
progressive respiratory failure who failed conservative
strategies.
• Further studies should identify patients who may
benefit from early surgical management and/or
transfer to a facility that has ECMO capabilities.
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Fifty Shades of Sarcoidosis:
A Case Report of Löfgren Syndrome
Arpana Paruchuri, MD

INTRODUCTION
Sarcoidosis is a multi-organ disorder that is characterized
by the presence of noncaseating granulomas in involved
organs. It commonly affects young and middle-aged
individuals of all races, but is 3-4 times more common in
African Americans and typically presents earlier with more
severe symptoms. 1 The lungs are affected in 90% of
patients and pulmonary disease accounts for the majority
of the morbidity and mortality associated with this disease.
However, approximately 30% of patients can present with
extrapulmonary findings and can have involvement of
other organs such as the skin and eyes.1 The various
presentations of sarcoidosis can make it challenging to
diagnose and can lead to delays in treatment. Therefore,
it is important for clinicians to recognize the wide variety
of manifestations of sarcoidosis. In this case report, we
present a case of sarcoidosis in a young man with
arthralgias and skin lesions.

CASE PRESENTATION
A 44-year-old African American male with a past medical
history of hypertension, prior treated syphilis and anal
warts presented with a three-week history of a constant,
throbbing headache at the top of his head and night
sweats. His headache was worse in the morning and
improved with nonsteroidal anti-inflammatory drugs
(NSAIDs). He noted a month prior that his eyes were red
and that his vision had become blurry and he was
prescribed glasses. Around that time he noticed a pruritic,
tender rash on the ink lines of his tattoos on his upper
extremities bilaterally. His tattoos were five years old and
he had not had any issues with them prior to this episode.
He also noticed tender, hard bumps on his lower
extremities bilaterally. He complained of night sweats,
chills, rigors, bilateral ankle pain, and weakness but denied
any neck pain, photophobia, confusion, chest pain,
shortness of breath, and cough. Of note, the patient had
been diagnosed with syphilis four years ago when he
presented with weakness in his lower extremities. His
symptoms reportedly improved after a gluteal injection of
an unknown medication. The patient’s social history was
positive for anal intercourse with his husband but he
denied any new partners in the last six months. His
husband was HIV positive but the patient reported that
they used condoms consistently. On exam, the patient
had a temperature of 100.9F, heart rate of 106 bpm, blood
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Figure 1. Skin findings of tender firm nodules along the ink-lines of the tattoo on the
patient’s upper extremity.

pressure of 166/96 mmHg, and oxygen saturation 100%
on room air. The only positive findings on physical exam
were multiple raised, firm, and tender nodules along the
ink-lines of both tattoos on bilateral upper extremities
(Figure 1) and three firm, erythematous, non-fluctuating
nodules on his lower extremities.

DIFFERENTIAL DIAGNOSIS
In a middle-age, African American male with fevers, ankle
pain, and new skin findings consistent for erythema
nodosum (EN) on his lower extremities, sarcoidosis
remained high on the differential despite the lack of
pulmonary symptoms. Based on his past medical and
social history, human immunodeficiency virus (HIV) and
neurosyphilis were also on the differential. Given the
patient’s symptoms at the time of syphilis diagnosis (lower
extremity weakness), the story seemed consistent for
neurosyphilis. However, given the fact that he received
only an intramuscular injection, it was unclear if he had
been treated properly for neurosyphilis which would
require IV Penicillin. Given his fever and tachycardia,
infection was on the differential as well. During the
work-up, the only abnormal labs were an elevated serum
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), and angiotensin-converting enzyme (ACE) level.
Blood cultures, HIV, rapid plasma reagin (RPR) test, and
sexually transmitted disease (STD) testing were negative.
A chest x-ray was unremarkable but a subsequent chest

CT showed bilateral multifocal pneumonia and possible
mild hilar lymphadenopathy. A punch biopsy of the tattoo
was performed which confirmed the presence of a
sarcoidal granulomatous tattoo reaction with negative
cultures. Given his clinical presentation of EN, hilar
lymphadenopathy, arthralgias and fever the patient was
diagnosed with Löfgren Syndrome.

OUTCOME & FOLLOW UP
The patient was discharged the following day with a
course of moxifloxacin for pneumonia and prednisone
40 mg daily with a plan to slowly taper. At his one-month
dermatology follow up, there was improvement of his
skin lesions and headaches. As his prednisone was
tapered during the next four months, he reported a return
of his headaches and new dyspnea on exertion. He was
started on hydroxychloroquine and told to follow up with
ophthalmology for clearance to continue this medication.
Unfortunately, the patient did not follow up for clearance
and hydroxychloroquine was discontinued.

DISCUSSION
This case emphasizes that sarcoidosis is a multisystem
disease with a variety of clinical presentations.2 About 50%
of patients diagnosed with sarcoidosis are asymptomatic
with a normal lung exam at the time of diagnosis.
However, sarcoidosis may present with pulmonary
symptoms including non-productive cough, dyspnea,
and chest pain along with fatigue, fever, joint pain, and
weight loss.3 The occurrence of sarcoid granulomas on
old scars or tattoos is a rare but well-recognized
phenomenon and can be the initial presentation of
sarcoidosis in some patients.4 A common presentation of
extrapulmonary sarcoidosis is the combination of hilar
lymphadenopathy, migratory polyarthralgia, and fever
with or without EN, also known as Löfgren syndrome.
Sarcoidosis is a diagnosis of exclusion that relies on a
combination of symptoms, radiologic findings, histologic
evidence of noncaseating granulomas in involved organs,
and exclusion of other known causes of granulomatous
inflammation such as lymphoma and tuberculosis. In the
absence of Lofgren’s syndrome, a tissue biopsy of the
most accessible lesion is needed for diagnosis. Chest
x-ray is the only routine imaging recommended for
suspected sarcoidosis and can show bilateral hilar
lymphadenopathy and pulmonary infiltrates. Chest CT
scans can be used in more atypical presentations. In
Löfgren syndrome, EN and arthralgias are managed with
NSAIDs. Based on consensus recommendations, only
patients with severe pulmonary symptoms are managed
with prednisone 20-40 mg/day that is slowly tapered.3
Since 60% of patients have recurrent symptoms, a
maintenance dose of prednisone 10-15 mg/day for 3-6
months is recommended. Extrapulmonary treatment is

determined individually and may be managed with a
similar steroid taper. In cutaneous disease, topical
high-potency steroids are the first-line treatment.
Additional systemic therapies include methotrexate and
hydroxychloroquine.3 Patients should follow up with a
rheumatologist or pulmonologist. Recognizing that
sarcoidosis can affect many organs and present with
non-specific symptoms is essential in order to diagnose
and treat this disease in a timely fashion.

KEY POINTS
• Common organs affected in sarcoidosis include the
lungs, skin and eyes.
• Extrapulmonary sarcoidosis can manifest as Löfgren
syndrome which is a constellation of symptoms and
objective findings including hilar lymphadenopathy,
migratory polyarthralgia, and fever with or without
erythema nodosum.
• Diagnosis of sarcoidosis is made from a combination
of symptoms, radiologic findings, evidence of
noncaseating granulomas in involved organs and
exclusion of other known causes of granulomatous
inflammation.
• Standard treatment of sarcoidosis is prednisone 20-40
mg/day that is tapered every 4-12 weeks and follow-up
with a rheumatologist or pulmonologist.
• If symptoms reoccur, maintenance therapy with
prednisone 10-15 mg/day can be continued for 3-6
months.
• In cutaneous disease, topical high-potency steroids,
methotrexate or hydroxychloroquine can be used.
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A Case of Cryptogenic Organizing Pneumonia
Managed without a Diagnostic Biopsy
Kamal Amer, MD, McKensie Walker, BSc, and Vincent Yeung, MD

INTRODUCTION
Organizing pneumonia (OP) is a type of diffuse interstitial
lung disease characterized by a specific histopathologic
pattern of response to lung injury. When the etiology of
the injury is unknown and in the absence of inflammatory
or connective tissue disease, this entity is termed
cryptogenic organizing pneumonia (COP) or primary
organizing pneumonia (POP). Disease states in which the
etiology of underlying injury is known is termed secondary
organizing pneumonia (SOP). Causes of SOP include drug
toxicity, chronic heart or renal failure, rheumatic disease,
collagen vascular disease, infection, immunodeficiency,
autoimmune disease, and interstitial lung disease.1
OP is characterized by the accumulation of inflammatory
cells, fibroblasts, and myofibroblasts in the lumens of
bronchioles and alveoli creating plugs of debris. This
leads to alveolar epithelial injury, which is followed by
leakage of plasma cells and the recruitment of fibroblasts
and fibrin within the alveolar lumen. This accumulation of
granulation tissue within the alveolar sacs extends into
the alveolar ducts as well as the bronchioles causing
symptom onset. The clinical presentation of OP is variable
and involves nonspecific symptoms such as mild fever,
cough, malaise, anorexia, weight loss, and progressive
dyspnea.2 Some reports describe wheezing and clubbing,
but these symptoms occur in only 5% of cases. While
“crackles” is the most common abnormal finding of OP
on auscultation, 25% of reported cases present with a
completely normal pulmonary exam.3
The decision to treat patients for OP depends on the
clinician’s ability to rule out other potentially reversible
causes of dyspnea as well as the number of criteria met
for this diagnosis of exclusion, based on histopathologic,
radiographic, and clinical findings.4 Diagnosis is made via
biopsy; though surgical biopsy via thoracoscopy
has remained the gold standard, trans-bronchial biopsy
has recently gained prevalence.5 We aim to present
a suspected case of COP as an uncommon cause of
interstitial lung disease.

CASE PRESENTATION
Our patient is a 75-year-old man with a past smoking
history of 50 pack-years as well as a history of heart failure
with preserved ejection fraction, hypertension, non-insulin
dependent type 2 diabetes mellitus, obstructive sleep
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Figure 1. Chest x-ray upon presentation with multifocal opacities.

apnea, peripheral vascular disease, and gout who
presented to the emergency department (ED) with one
week of shortness of breath and dyspnea on exertion. He
did not endorse any associated fevers, productive cough,
sick contacts, weight loss, paroxysmal nocturnal dyspnea,
or chest pain. He had stable orthopnea and lower
extremity edema. On arrival to the ED, he was hypoxemic
to 72% on room air and required 4 liters of oxygen via
nasal cannula to maintain oxygen saturations above 90%.
His chest x-ray demonstrated multifocal opacities with a
left lung predominance that was distinct from prior
imaging studies (Figure 1). He was started on a course of
broad spectrum antibiotics (vancomycin and zosyn)
without clinical improvement. His oxygen requirements
increased and he was transitioned to 6 liters of oxygen via
nasal cannula with a periodic need for continuous positive
airway pressure (CPAP).
A computed tomography (CT) scan of his chest
demonstrated diffuse patchy bilateral airspace opacities
with lower lobes predominance as well as scattered
ground-glass opacities concerning for multifocal
pneumonia (Figure 2). He had a speech and swallow
assessment to evaluate for aspiration, which was
negative. Sputum cultures and blood cultures were
negative. Urine streptococcal and legionella antigens,
influenza and RSV viral swabs, as well as a MRSA swab
were sent but failed to identify a pathogen for the

Figure 2. Computed tomography scan of the chest showing patchy bilateral
airspace opacities, most predominant in the lower lobes, with associated scattered
ground-glass opacities bilaterally.

patient’s suspected pneumonia. He also underwent
evaluation for autoimmune and connective tissue
diseases that could have contributed to his presentation,
with negative ANA, ANCA, anti-Scl 70, anti-dsDNA, and
anti-Jo1 testing. He never presented with an elevated
eosinophil count.
Prednisone was added to his empiric broad spectrum
antibiotics given concern for possible organizing
pneumonia based on his imaging findings with clinical
improvement. By the third day of his admission, the
oxygen saturations were consistently 98% on 2L nasal
cannula. His antibiotics were de-escalated to moxifloxacin
to complete a five-day course and he was started on a
prolonged prednisone taper to empirically treat
cryptogenic organizing pneumonia, as the patient
declined surgical and trans-bronchial biopsy to confirm
this suspicion. At the time of discharge, he was stable on
room air at rest but required 1-2L of supplemental oxygen
with ambulation and CPAP at night.

FOLLOW UP
The patient was followed closely at the outpatient
pulmonary office. He was readmitted every couple of
months after his initial presentation with shortness of
breath and increased work of breathing that notably flared
toward the end of his prednisone tapers and rapidly
improved with intravenous steroids administered in the
hospital. These admissions were attributed to COP flares
though his diagnosis was never confirmed; an infectious
workup as detailed during his initial admission were
repeated at each subsequent admission and was similarly

negative every time. The last time he was seen in the
outpatient pulmonary office, he reported fevers at home
with a newly-productive cough. His outpatient labs
demonstrated a leukocytosis of 16.1 billion/L, although
whether this was related to ongoing steroid use or
underlying infection was uncertain. He was readmitted
and started on stress-dose steroids as well as broadspectrum antibiotics and anti-fungal therapy, as a repeat
CT scan revealed a worsening of the diffuse airspace
opacities seen on prior imaging studies concerning for
superimposed infectious pneumonia. His sputum cultures
at this interval grew yeast. He developed hypoxic
respiratory failure, requiring intubation and tracheostomy,
and septic shock complicated by disseminated
intravascular coagulation and pulseless ventricular
tachycardia resulting in his eventual death. The patient’s
family declined autopsy.

DISCUSSION
Treatment of COP has not been well evaluated in clinical
trials and therefore is based upon clinical experience.
Prednisone is the first-line treatment for COP due to its
anti-inflammatory effects and 65-85% of patients respond
to this therapy.6 Relapses are common in up to 58% of
cases and are associated with corticosteroid tapers.7,8 For
refractory or recurrent cases, Vaz et al. found macrolides
to be effective at achieving remission after one year of
treatment. 9 Cytotoxic and immunomodulating agents
such as rituximab have also shown efficacy in treating
refractory COP in preliminary case reports.10 In patients
where steroids are difficult to taper, azathioprine has been
suggested as a steroid-sparing agent although evidence
for this therapy is limited.11 Cyclophosphamide has also
been used in patients who fail to improve with glucocorticoids but data regarding its use is similarly sparse.12
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About 33% of patients who are treated for less than one
year with corticosteroids experience recurrence.13 Studies
have shown that relapse is associated with multiple
factors such as gastroesophageal reflux disease, a
decrease in functional vital capacity, a decrease in serum
protein, and severity of illness at diagnosis.2,14,15 Lazor et al.
studied relapses in 48 cases and found that a delay in
initial diagnosis was also associated with an increase in
relapse.8 Watanabe et al. found that the level of hypoxemia
at time of diagnosis was the most important factor in
predicting relapse.7
In this report, we described a patient with suspected COP
based on clinical presentation and response to empiric
prednisone with recurrence of presenting symptoms
toward the end of prolonged steroid tapers. His negative
infectious workup during each of his four hospital
admissions and his negative evaluation for autoimmune
and connective tissue diseases helped guide our clinical
suspicion for COP even in the absence of a confirmatory
biopsy. Our patient originally presented with recurrent
episodes of presumed community-acquired pneumonia.
The most common presentations of COP are nonspecific
flu-like symptoms such as cough, fever, dyspnea, and
malaise; most patients are thus started on antibiotic
treatment but remain unresponsive to this therapy. As this
case reflects, the diagnosis of COP is usually delayed and
therefore a high index of suspicion is required to correctly
and promptly address this disease.
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Amyotrophic Lateral Sclerosis Presenting
as Chronic Cough
Marjorie Friedman, MD

INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a debilitating,
uniformly fatal disease. While it most commonly
presents with limb weakness, patients may also present
with neurocognitive, respiratory, or bulbar symptoms.
Despite its poor prognosis, an early diagnosis can save
patients from unnecessary and expensive testing, lead
to interventions that improve quality of life, and give
patients and family time for advanced planning.1 This
case highlights an unusual presentation of ALS.

CASE PRESENTATION
A 77-year-old male with a past medical history of coronary
artery disease, three-vessel coronary artery bypass graft
surgery, mild chronic obstructive pulmonary disease
(COPD) and a 40 pack year cigarette smoking history
presented with a chief complaint of cough which began
in March 2016. His only other complaint was mild dyspnea
on exertion. He was treated twice with oral steroids and
antibiotics as an outpatient for COPD exacerbations
without improvement. In August 2016, he saw a new
pulmonologist for his persistent cough. The pulmonologist
obtained a chest xray and pulmonary function tests
(PFTs) (Table 1), and adjusted his medications. The chest
xray showed a left hemidiaphragm elevation but was
otherwise unremarkable. A follow up fluoroscopic sniff
test showed no evidence of paradoxical motion.
He initially presented to the hospital in October 2016, and
complained of coughing fits and progressive dyspnea on
exertion. His cough was productive of yellow sputum
and worse with lying flat. He also complained that his
voice had a new nasal quality. He denied heartburn,
dyspepsia, post nasal drip, lower extremity edema or
chest pain. His vital signs were within normal limits and
he appeared well. Cardiac exam was normal. He had
scattered expiratory wheezes and no clubbing. Admission
labs are listed in Table 2.

DIFFERENTIAL DIAGNOSIS
The patient’s chief complaint was a chronic cough. The
patient did have a history of smoking, a diagnosis of
COPD, and ACE inhibitor use, all of which are commonly
associated with cough. Excluding these risk factors, the
most common causes of chronic cough are upper

Table 1: PFTs from September 2016
%
Predicted

% Predicted:
After bronchodilator
challenge

111%

110%

FEV1

52%

57%

TLC

45%

RV

36%

DLCO

68%

DLCO/VA
(corrects for alveolar
volume)

133%

FEV1/FVC

Table 2: The Patient’s Admission Labs
Patient Result

Normal Value Range

WBC

9.7 B/L

4-11 B/L

Hgb

14.6 g/dL

14.0-17.0 g/dL

Platelets

193 B/L

140-400 B/L

Creatinine

1.3 mg/dL

0.7-1.4 mg/dL

Bicarbonate

21 mmol/L

24-32 mmol/L

Troponin T

< 0.01 ng/mL

< 0.01 ng/mL

proBNP

33 pg/mL

< 450 pg/mL

VBG pH

7.36

7.32-7.43

VBG CO2

59 mmHg

38-50 mmHg

Lactate

2.2 mmol/L

0.5-2.0 mmol/L

TSH

0.22 uIU/mL

0.3-5.0 uIU/mL

Free T4

1.1 ng/dL

0.7-1.7 ng/dL

airway cough syndrome, asthma, and GERD.2 However,
the patient’s abnormal PFTs provided a starting point for
evaluating his symptoms.
The patient’s PFTs were most notable for restrictive lung
physiology: FEV1/FVC ratio was elevated, and TLC was
markedly low. The 11% absolute change in his FEV1 with
bronchodilator challenge suggested an element of
obstruction as well (close to the cutoff of 12% generally
used). However, given that the FEV1/FVC ratio was
elevated and repeated treatments for COPD exacerbations
did not relieve his symptoms, it was thought that his
presentation was not entirely explained by COPD alone.
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The differential diagnosis for restrictive lung physiology
includes interstitial lung disease (ILD), extrinsic disorders
that cause chest wall compression such as kyphosis or
obesity and neuromuscular disorders. The patient had
no evidence of ILD on chest CT. The elevated DLCO/VA
on PFTs implied no issues with diffusion of gases across
the alveoli membrane which further argued against ILD.
The patient was mildly obese with a body mass index of
33, but his habitus was not thought to be sufficient
enough to cause extrinsic restriction to the degree seen
on his PFTs. The differential diagnosis of neuromuscular
disorders that cause restrictive lung disease can be
divided into the following categories: spinal cord disease
such as multiple sclerosis, motor neuron disease such
as amyotrophic lateral sclerosis (ALS), neuromuscular
junction disease such as myasthenia gravis and muscle
disease such as polymyositis.

OUTCOME AND FOLLOW-UP
During his initial hospitalization, the patient received
nebulizers and a course of steroids and moxifloxacin.
Additional laboratory work to evaluate for neuromuscular
disorders (arterial blood gas and creatine kinase) was
unremarkable. Neurology was consulted but did not
consider the patient’s history and physical exam
concerning for a neuromuscular disease. His symptoms
improved and he was discharged.
A week later, he returned to the emergency room
complaining of severe dyspnea, wheezing and a
persistent cough that woke him from sleep. Although
compliant with medications, he experienced little
symptomatic relief. He was admitted to the hospital and
underwent a transthoracic echo and CT of the sinuses
both of which were unremarkable. His symptoms
improved within one day and he was again discharged.
The patient was referred to otolaryngology as an
outpatient who started the patient on a trial of omeprazole
for laryngospasm and tramadol for neurogenic cough.
In November 2016, the patient presented again. His
symptoms had progressed to the point that he had to
sleep upright in a chair and could not catch his breath
after walking up a flight of stairs. His initial oxygen
saturation was 80% on room air. He was again treated
with nebulizers and antibiotics and admitted for further
workup. After several days he was noted to have fasciculations of his hand muscles. An EMG was performed and
results were consistent for ALS.
Before discharge, the patient was seen by palliative care
for assistance with coping with his diagnosis and
advanced care planning. He was discharged home on
BiPAP which led to a profound improvement in his sleep,
dyspnea, and cough. He continues to follow regularly
with Jefferson pulmonology and neurology at the
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Jefferson Weinberg ALS Center and has only been
admitted to the hospital once since the diagnosis was
made.

DISCUSSION
The average time between onset of symptoms and
diagnosis of ALS is 13-18 months.1 The majority of ALS
cases (70-80%) present initially with asymmetric limb
weakness whereas respiratory symptoms are present in
about 5% of patients and bulbar symptoms (such as
hoarse voice and laryngospasm) are present in only
about 20%. 3 Given the rarity of ALS (incidence of
2:100,000 in western countries), patients tend to undergo
treatment of more common conditions prior to diagnosis
of ALS as seen in our case.3 Also, our patient did not have
a classic presentation of ALS which added to the delay in
his diagnosis.
In addition to providing a unique presentation of ALS,
our patient’s case highlights several important features
of caring for patients with ALS. Non-invasive positive
pressure ventilation (NIPPV) is an important tool that has
been shown to improve quality of life and increase
survival by an average of 15 months.4 Advanced care
planning is also crucial for patients diagnosed with ALS
and should involve creation of a living will, appointing a
power of attorney, and discussions regarding PEG and
tracheostomy placement. Continued healthcare at a
multidisciplinary center for ALS, which our patient
receives, has been shown to lead to better outcomes.1

KEY POINTS
• Our patient presented with chronic cough and
restrictive lung disease and after extensive workup was
diagnosed with ALS.
• Bulbar and respiratory symptoms are uncommon
initial presentations of ALS.
• Early diagnosis of ALS can allow for advanced care
planning and help patients initiate treatment earlier
which can lead to improved quality of life.
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Adverse Effects of Checkpoint Inhibitor
Immunotherapy in Medical Oncology
Michael Brister, MD and Colin Thomas, MD

INTRODUCTION
The development of checkpoint inhibitor immunotherapy
marks a significant innovation in the field of medical
oncology over the past decade. Checkpoint inhibitors
are antibody drugs that have demonstrated efficacy in
treating a wide range of malignancies including
advanced melanoma, non-small cell lung cancer, and
Hodgkin lymphoma. These drugs antagonize
cell-associated molecules responsible for immunologic
down-regulation including programmed cell death
receptor 1 (PD-1), programmed cell death ligand 1
(PD-L1) and cytotoxic T-lymphocyte-associated antigen
4 (CTLA-4). Curtailing the function of these intrinsic
immunologic down-regulators enhances the body’s
own antitumor immune mechanisms. Despite the
promise of these new therapies, a variety of immunerelated adverse events (irAEs) have been described.1,2
Utilization of immunologic checkpoint blockade is
increasing in medical oncology, and the importance of
understanding these new toxicities is evident. Here we
discuss some of the most important adverse effects of
checkpoint inhibitors and review the basic principles of
managing these conditions. There is a lack of strong
evidence guiding the optimal management of irAEs, but
treatment algorithms exist based on clinical experience.

GASTROINTESTINAL TOXICITY
The most common gastrointestinal irAEs are diarrhea
and colitis. Symptoms generally develop about 6-8
weeks after treatment initiation. 3 Whereas diarrhea is
based on an increase in stool frequency or ostomy
output compared to baseline, indicators of colitis include
stools with blood or mucus, or the presence of
abdominal pain and cramping. Enteritis involves
symptoms similar to colitis, but anatomically the small
bowel is affected. Esophagitis and gastritis have also
been reported as irAEs, but are much less common.
Gastrointestinal irAEs are more frequent in patients
treated with CTLA-4 targeting therapy such as ipilimumab,
compared with PD-L1 or PD-1 inhibitors such as
Nivolumab.4,5 In a study of patients with melanoma
receiving ipilimumab monotherapy, 28% developed
diarrhea and 8% developed colitis. Interestingly, 5% of
patients developed severe (grade 3/4) colitis. 4,6
Gastrointestinal irAEs frequently reach grade 3/4 in
severity, thus early recognition and appropriate
management is important to reduce the risk of
life-threatening complications such as bowel perforation.
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Patients that develop diarrhea or abdominal pain while
on checkpoint inhibitors should first be evaluated for
infectious diarrhea including C. difficile. If infectious
diarrhea can be excluded and symptoms persist or
worsen, an adverse reaction to immunotherapy becomes
more likely. However, it is difficult to make this distinction
definitively and treatment is often empiric. The Common
Terminology Criteria for Adverse Events (CTCAE) defines
grade 1 diarrhea as an increase of fewer than four stools
per day above baseline, and patients with grade 1 colitis
are usually asymptomatic. These patients are treated
symptomatically with loperamide or diphenoxylate and
atropine, and immunotherapy may be resumed as
scheduled with close monitoring and patient education.
Grade 2 diarrhea is defined as four to six stools per day
above baseline, and grade 2 colitis is defined by the
presence of abdominal pain or bloody stools. For these
patients, checkpoint inhibitor therapy should be stopped
until symptoms improve to grade 1 with symptomatic
management. However, if symptoms persist for more
than 5 days, systemic corticosteroids should be begun at
a dose of 0.5-1.0 mg/kg/day of intravenous (IV) methylprednisolone or the oral equivalent. In this case,
colonoscopy or computed tomography (CT) evaluation
is helpful to confirm the diagnosis. If symptoms worsen
or do not improve within 3 days of steroid treatment, the
diarrhea or colitis should be managed as grade 3/4 with
1.0-2.0 mg/kg/day of IV methylprednisolone, and the
immunotherapy should be permanently discontinued.
Steroids may only be tapered after symptoms improve to
grade 1, and the taper should be performed slowly over
at least 1 month. If symptoms do not improve to grade 1
and persist for more than 3 days despite higher steroid
dosing, it is recommended to add infliximab to the
treatment regimen, similar to the management of active
inflammatory bowel disease (IBD).7 Grade 3/4 diarrhea is
defined as seven or more stools per day above baseline,
and grade 3/4 colitis includes severe abdominal pain,
sometimes with peritoneal signs. If intestinal perforation
has occurred, infliximab use is contraindicated.
Patients with hepatotoxicity from checkpoint inhibitor
therapy are usually asymptomatic and patients are
diagnosed based on increased levels of aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and/or total bilirubin noted 8 -12 weeks af ter
immunotherapy initiation. Occasionally, mild symptoms
are present including fatigue or fever, but death from
fulminant hepatitis has also been reported.8 Grade 2
hepatotoxicity is based on measurement of AST or ALT

2.5-5 times the upper limit of normal, or total bilirubin
1.5-3 times the upper limit of normal. Grade 3 or grade
4 hepatotoxicity is defined as AST or ALT greater than 5
times the upper limit of normal or total bilirubin greater
than 3 times the upper limit of normal. In the CheckMate
067 phase III trial, both nivolumab monotherapy and
ipilimumab monotherapy were associated with an 8%
incidence of hepatotoxicity based on any grade of
transaminase elevation, and grade 3/4 transaminase
elevations occurred in 2% of both patient groups.9
Patients receiving combination nivolumab plus
ipilimumab had a much higher rate of transaminitis, with
33% of patients developing hepatic injury of any grade.
Management should include exclusion of other causes
of hepatitis, including medication-induced hepatic injury
or viral hepatitis. As with other irAEs, immunotherapy
should be delayed if grade 2 toxicity is present. With
grade 3 or 4 hepatotoxicity, immunotherapy should be
discontinued indefinitely and steroids should be started
at a dose of 1.0-2.0 mg/kg/day of IV methylprednisolone
or oral equivalent. Mycophenolate mofetil may be added
if there is no improvement within 3 days. Unlike treatment
of severe immunotherapy-related diarrhea or colitis,
grade 3/4 hepatotoxicity should not be treated with
infliximab, as this drug has been independently implicated
as a cause of medication-induced hepatotoxicity.

PNEUMONITIS
Pneumonitis is a potentially fatal complication of
checkpoint inhibitor immunotherapy. This is a particularly
important consideration in patients with compromised
pulmonary reserve including those who have had
radiation therapy, lung resection, or patients with a
history of exposure to chemotherapies associated with
pneumonitis such as bleomycin, docetaxel, or
gemcitabine. In an early phase study of nivolumab
monotherapy, deaths due to pneumonitis were reported
in 2 patients with non-small cell lung cancer and 1
patient with colorectal cancer, in total representing 1%
of patients in this study. 10 Pneumonitis caused by
checkpoint inhibitors can be difficult to diagnose and
the clinical manifestations are diverse. In one study,
pneumonitis presented up to 19 months after initiation
of checkpoint inhibitor therapy, with a median time to
onset of about 3 months. However, one-third of patients
were asymptomatic at the time of diagnosis and were
identified based on radiologic findings alone, suggesting
an even later median time to onset clinically.11 When
symptoms were present, patients presented with
dyspnea, cough, fever, or chest pain.
Before diagnosing immunotherapy-related pneumonitis,
more common etiologies of pulmonary symptoms
must be excluded. Caution should be taken to rule out
infection, often in association with an infectious disease

consultation. Previously undiagnosed malignancy
infiltrating the lungs must also be considered, and
pulmonary consultation is advised when there is
concern for grade 2 pneumonitis (mild to moderate
new symptoms). CT imaging is helpful to guide
diagnosis, and bronchoscopy or lung biopsy may also
be warranted, but there are no radiographic or
pathologic findings specific to pneumonitis caused by
checkpoint inhibitor exposure.
Grade 1 toxicity involves radiographic changes only and
requires repeat imaging every 3 weeks to assess if
immunotherapy should be delayed. Grade 2 toxicity
should be managed with 1.0 mg/kg/day of methylprednisolone or the oral equivalent, and doses of 2.0-4.0
mg/kg/day are recommended for grade 3 or higher
toxicity. Prophylactic antibiotics for Pneumocystis
pneumonia (PCP) should be added if the patient will
require the equivalent of 20 mg of prednisone daily for
greater than 4 weeks. If patients do not improve after 48
hours of steroid therapy, additional immunosuppression
with infliximab, cyclophosphamide, intravenous
immunoglobulin, or mycophenolate mofetil should also
be considered. In a group of 43 patients receiving PD-1/
PD-L1 inhibitor therapy who were diagnosed with
immunotherapy-related pneumonitis, 86% improved
with either corticosteroid administration or discontinuation of immunotherapy. Of the remaining 6 patients, 5
died from either infection or cancer progression.11 In a
comparison of PD-1 inhibitors to PD-L1 inhibitors for the
treatment of non-small cell lung cancer, PD-1 inhibitors
were found to be more than twice as likely as PD-L1
inhibitors to cause pneumonitis (3.6% versus 1.3%).12

ENDOCRINOPATHIES
The endocrine system relies on finely tuned quantities
of hormones controlling target organs, and the body is
especially sensitive to altered levels of endocrine
signaling. Unlike other organ systems adversely affected
by immune checkpoint blockade, endocrine organ
dysfunction from checkpoint inhibitors does not readily
reverse with corticosteroids. 13 Life-long hormone
supplementation is required in many patients with
endocrine irAEs. In a phase 3 trial of patients receiving
ipilimumab and nivolumab, more than 50% of patients
who developed any grade of endocrine toxicity required
long-term hormone supplementation. Even so,
substantial improvement in symptoms was observed.9
Endocrinopathies can present a diagnostic challenge
because patients develop non-specific complaints
including fatigue, weakness, nausea, and abdominal
pain. The anterior pituitary is critical for thyroid function,
gonadal function, and adrenal activity. The most common
endocrine irAEs are hypothyroidism, hyperthyroidism,
and hypophysitis. In a study of patients receiving
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ipilimumab for melanoma, 8% developed hypophysitis
and 6% developed thyroiditis.14 There is variability in the
time to onset of endocrine-related adverse effects, with
a trend towards later presentations compared with irAEs
affecting other organ systems. In patients receiving
ipilimumab, the median time to onset of hypophysitis
was observed to be between 4-8 weeks after treatment
initiation, but patients have been diagnosed with
immunotherapy-related thyroiditis up to 3 years after
treatment initiation, including long after checkpoint
inhibitor therapy has been discontinued.14,15
Patients suspected to have endocrine irAEs should have
laboratory testing of thyroid-stimulating hormone (TSH),
triiodothyronine (T3), thyroxine (T4), adrenocorticotropic hormone (ACTH), follicle-stimulating hormone
(FSH), luteinizing hormone (LH), and cortisol. These
tests should be repeated at regular intervals in patients
diagnosed with endocrine irAEs. If there is concern for
hypophysitis, the patient should undergo visual field
testing and pituitary MRI should be considered to assist
in confirming the diagnosis. Patients with hypophysitis
who become symptomatic should be treated with
1.0-2.0 mg/kg/day of methylprednisolone or the oral
equivalent. Immunotherapy treatments should be
delayed and appropriate hormone replacement therapy
should be started. If the complication is grade 4
(life-threatening), checkpoint inhibitor treatments must
be permanently discontinued. Prophylactic antibiotics
for PCP should be considered, and if symptoms improve,
steroids may be tapered over a minimum of 1 month,
but usually longer.
Thyroiditis secondary to checkpoint inhibitors often
presents similarly to Hashimoto’s thyroiditis with a period
of clinical hyperthyroidism preceding a progressive
transition towards hypothyroidism over several weeks.
In cases of asymptomatic TSH elevation, immunotherapy
may be continued; however, patients with a TSH that is
less than half the lower limit of normal, or greater than
2 times the upper limit of normal, should have free T4
testing with each cycle of immunotherapy. If hypothyroidism is present, the patient should be started on
levothyroxine, but in contrast to the treatment of most
irAEs, it is unclear if steroids are helpful in the long-term
management of symptomatic thyroiditis.
Less common endocrine irAEs include primary adrenal
insufficiency and type 1 diabetes mellitus, which have
each been observed in less than 1% of patients. 16,17
The development of adrenal crisis is a dangerous
complication that must be differentiated from sepsis
and immediately treated with intravenous corticosteroids. Immunotherapy-related endocrinopathies are
variable in presentation, often permanent, and require
careful consideration in patients exposed to checkpoint
inhibitors presenting with vague systemic complaints.
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CONCLUSION
Immunotherapy is becoming increasingly prevalent in
medical oncology. Studies have indicated checkpoint
inhibitors are better tolerated and associated with fewer
adverse effects overall in comparison with standard
chemotherapy, 18 but the toxicities associated with
immunotherapy are often difficult to recognize and may
affect several organ systems. The most important irAEs
are diarrhea, colitis, hepatitis, pneumonitis, and endocrinopathies. The skin, however, is the most commonly
involved organ, and the most frequently observed
cutaneous toxicity is a mild pruritic maculopapular rash.
Less common toxicities include myocarditis, encephalitis,
uveitis, inflammatory arthritis, and kidney injury. The
various toxicities associated with immunotherapy may
present clinically as early as several weeks after
checkpoint inhibitor initiation, or may not manifest for
several years.
Management of suspected irAEs typically includes ruling
out infectious causes of symptoms, delaying further
immunotherapy, and initiating treatment with corticosteroids. Endocrinopathies related to checkpoint
inhibitors are often irreversible and require indefinite
hormone replacement therapy. There are no prospective
trials guiding management of irAEs. Future studies
should aim to identify subpopulations of patients most
at risk for developing severe irAEs, and rigorous trials
should evaluate optimal management of these toxicities.
Clinicians from many specialties must be aware of the
spectrum of immune-related toxicities associated with
checkpoint inhibitors, as these medications are being
used to treat an increasing number of cancer patients,
and immunotherapy holds immense promise in the
field of medical oncology.
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Sclerosing Mesenteritis: Clinical Presentation,
Imaging Findings, and Treatment
Jennifer Nauheim, BSc and Rose Onyeali, MD

CASE PRESENTATION
A 67-year old male with a history of myocardial infarction
status post percutaneous coronary intervention and
stage IV bladder cancer status post radical cystoprostatectomy with ileal neobladder reconstruction and
chemotherapy (cisplatin and gemcitabine) presented
with progressive, severe epigastric and lower abdominal
pain associated with nausea. The pain had intensified
over the previous week and was associated with a recent
fifteen pound weight loss in the setting of poor oral
intake. He denied nausea or diarrhea.
His physical exam was notable for abdominal tympany
and tenderness. His labs were notable for mild
hyperkalemia (potassium 5.0 mmol/L), normal white
blood cell count, lipase of 28 U/L, normal liver function
tests, and positive 2+ leukocyte esterase and 1+ blood in
his urine. Upper endoscopy showed a small Schatzki's
ring in the distal third of the esophagus with small hiatal
hernia and gastritis. On CT, there was thickened, indurated
mesentery and a mesenteric mass (Figure 1) with
abdominal lymphadenopathy and a new adrenal nodule.

Figure 1. CT of the patient’s abdomen showing a thickened, indurated mesentery.

EPIDEMIOLOGY & CLINICAL PRESENTATION
Sclerosing mesenteritis, also known as mesenteric
panniculitis, is part of a spectrum of idiopathic primary
inflammatory and fibrotic processes that affect the
mesentery and is characterized by inflammation of
mesenteric fat. Although its etiology is unclear, it has
been associated with previous abdominal surgery,
autoimmunity, paraneoplastic syndromes, ischemic
injury, and infection. Sclerosing mesenteritis is also
associated with a high prevalence of coexisting
malignancies and future cancer development. 1 In a
study evaluating 7620 patients presenting with a chief
complaint of abdominal pain, the prevalence was 0.6%.2
The presentation of sclerosing mesenteritis is variable.
In a series of 68 patients with sclerosing mesenteritis,
75% had abdominal pain, 26% had nausea/vomiting,
20% had anorexia and weight loss, and 20% had altered
bowel habits.3 In an 84-patient cohort, only 35% had
abdominal pain, and 20% had an incidental abdominal
mass on exam. 2 The duration of symptoms ranged
from 24 hours to 2 years.2
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Figure 2. Fat ring sign (white arrow) seen on CT abdomen.

Up to 20% of patients with sclerosing mesenteritis
develop complications, often intestinal obstruction from
mass effect.3 Other complications include mesenteric
vascular occlusion, chylous ascites, and adverse effects
from medications used to treat sclerosing mesenteritis.

OUTCOME & DISCUSSION
The patient was started on tamoxifen and steroids for
his sclerosing mesenteritis, but a biopsy of the enlarged
abdominal lymph nodes and the adrenal nodule
demonstrated worsening metastatic malignancy.
Medical oncology advised that the patient discontinue
tamoxifen and taper the steroids because of a lack of
improvement in his abdominal pain. The patient received
a celiac nerve block as an outpatient without any
complications.

Figure 3. Tumor pseudocapsule (white arrow) seen on CT abdomen.

DIAGNOSIS
The diagnosis of sclerosing mesenteritis is made by
histology and radiographic findings, with noninvasive
imaging being preferred over surgical sampling. Dual
phase computed tomography is the most sensitive
imaging modality for detecting sclerosing mesenteritis.
Sclerosing mesenteritis typically presents on imaging as,
in decreasing order of frequency, diffuse mesenteric
thickening, a single mass with an average size of 10 cm,
or multiple masses. 2 “Misty mesentery,” haziness and
stranding in the mesenteric fat, can be observed in
sclerosing mesenteritis, but is not a specific imaging
finding. The “fat ring sign,” fat around mesenteric vessels
spared from the changes of mesenteric panniculitis, is
seen in 56 -90% of cases (Figure 2). A tumoral
pseudocapsule is ocassionally seen (Figure 3). These
latter two findings are not seen in other mesenteric
diseases such as lipoma, lymphoma, or liposarcoma.4

The differential diagnosis of a patient presenting with
abdominal pain is broad. The differential for this patient
after imaging included idiopathic sclerosing mesenteritis
in the setting of metastatic bladder cancer, constipation
secondary to opioid pain medications, narcotic bowel
syndrome, pancreatitis, and worsening metastatic
disease. It is likely that this patient’s abdominal pain was
multifactorial: his initial CT of his abdomen showed
evidence of sclerosing mesenteritis with abdominal
lymphadenopathy and an adrenal mass that were found
on biopsy to be metastatic foci.
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TREATMENT
The preferred first-line therapy for sclerosing mesenteritis
includes glucocorticoids in combination with tamoxifen,
although glucocorticoids alone or with colchicine/
azathioprine may be beneficial.5 Patients with greater
inflammatory components respond best to these
regimens. A response to hormonal therapy with
tamoxifen and progesterone has been reported as well.6
In refractory cases, thalidomide has been used.
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Syncope Diagnosed by Inducible Sustained
Ventricular Tachycardia
Amit Vira, MD

INTRODUCTION
Syncope is a common complaint in the emergency
department (ED), accounting for approximately 3% of
all ED visits.1 Although most causes of syncope are
benign and self-limited, others are associated with
significant morbidity and mortality.

CASE PRESENTATION
An 85-year-old male with a history of coronary artery
disease status post prior coronary artery bypass grafting,
moderate to severe aortic stenosis, hypertension, and
stage IIIA chronic kidney disease presents to emergency
room after abrupt onset of unwitnessed syncope. He
reports exercising on an elliptical machine at home and
falling on the floor. He denies any prodrome symptoms
of chest discomfort, shortness of breath, palpitations,
flushing, feeling cold or clammy, visual disturbances,
nausea or vomiting. He believes the episode was brief
and woke up within seconds feeling completely back to
his baseline. He denies any confusion, bladder or bowel
incontinence, or physical trauma immediately after the
syncope. He reports waking up that morning feeling
well, eating a normal breakfast and staying well-hydrated.
His medications include aspirin, atorvastatin, amlodipine,
and rampiril. He has no known tobacco, alcohol, or illicit
drug use.

Physical exam: Temperature 98.4 °F, Blood pressure
129/62, Heart rate 82, Respiratory rate 16, saturating 99%
on ambient air. Orthostatic vitals were negative. Cardiac
exam revealed a regular 3/6 mid-peaking systolic
ejection murmur with preservation of S2 at the cardiac
base. No jugular venous distention. Lungs were clear to
auscultation and the abdomen exam was soft,
non-tender, with normoactive bowel sounds. Extremities
were warm with +2 equal peripheral pulses. Neurologic
exam was non-focal with normal gait.
Laboratory Studies: Metabolic panel was significant for a
creatinine of 1.4 mg/dL (at baseline) with the remainder
of the electrolytes being normal. Complete blood count
was significant for a hemoglobin level of 12.3 g/dL (at
baseline). His serial cardiac enzymes were negative.
EKG showed normal sinus rhythm, normal QRS duration,
corrected QT of 455 ms, incomplete right bundle branch
and multiple premature ventricular complexes. An
echocardiogram revealed low normal right and left
ventricular function with inferoapical akinesis consistent
with an old infarcted scar and moderate aortic stenosis
with a mean gradient of 30 mmHg and valve area of 1.0
cm2, which was unchanged from a prior echocardiogram. 24-hour telemetry revealed multiple premature
ventricular complexes and short runs of non-sustained
ventricular tachycardia (Figure 1).

Figure 1. Patient’s continuous
cardiac monitoring revealed
multiple premature ventricular
complexes (seen on EKG) and
short runs of non-sustained
ventricular tachycardia.
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OUTCOME
Given his abrupt exertional syncope during exercise
without prodrome, cardiac syncope was suspected. EKG
showed evidence of conduction disease and significant
ventricular ectopy. His overall echocardiogram was
unchanged from prior and showed focal scar. Given this
constellation of signs and symptoms, a ventricular
tachyarrhy thmias was suspected as the cause.
Electrophysiologic study was recommended and
revealed an easily inducible sustained monomorphic
ventricular tachycardia. The ventricular tachycardia
showed a right bundle branch pattern with left superior
axis morphology consistent with an inferoapical site with
the likely origin being from the scar from his prior
myocardial infarction as seen on echocardiogram. Given
these findings, an implantable cardioverter defibrillator
was recommended for secondary prevention.

DISCUSSION
Syncope or “true syncope” is the sudden and transient
loss of consciousness and postural tone attributable to
inadequate cerebral blood flow. In comparison,
pre-syncope refers to near loss of consciousness and
occurs more commonly than syncope. However, both
syncope and pre-syncope should be considered in the
same disease spectrum.
There are many causes for transient loss of consciousness
(Table 1). Non-syncopal causes of transient loss of
consciousness include seizure disorders, concussions,
intoxications, metabolic disturbances, and conversion
disorders. Distinguishing these conditions from true
syncope is challenging, but it is crucial in order to
determine appropriate management.
The differential diagnosis of true syncope is broad, and
management focuses on treating the underlying cause.
Below are the most common causes of syncope seen in
emergency rooms.
1.

Neurally mediated syncope is one of the most
frequent etiologies of syncope and is often referred
to as vasovagal syncope. 2 It is characterized by
peripheral vasodilation and hypotension, along with
bradycardia which is believed to be due an increase
in parasympathetic tone and concomitant inhibition
of sympathetic outflow.3 The hypotension can lead
to loss of consciousness if severe or pre-syncope if
less severe. A wide variety of stimuli can trigger this
reflex, the most common stimulus being orthostatic
stress. Other triggers include prolonged standing,
crowded places, or unpleasant sight, smell, or pain.
Typically, one experiences nausea, lightheadedness,
a feeling of warmth, and pallor before losing
consciousness.

Table 1: Common Causes of Syncope
Neurally mediated
Vasovagal (emotional stress, pain, standing)
Orthostatic hypotension
Drug induced (alpha-blockers, vasodilators)
Hypovolemia (dehydration, blood loss)
Diabetic neuropathy
Parkinson’s disease
Dementia
Aging
Cardiac arrhythmias
Supraventricular tachyarrhythmias
Ventricular tachyarrhythmias
Torsade de pointes
Sinus bradycardia
High-grade atrioventricular blocks
Pacemaker malfunction
Cardiac non-arrhythmias
Advanced cardiomyopathy
Aortic stenosis
Hypertrophic obstructive cardiomyopathy
Pulmonary embolism
Pulmonary stenosis
Pericardial tamponade
Acute myocardial infarction
Aortic dissection

Table 2: High Risk Criteria Requiring Prompt Hospitalization
Severe structural or coronary artery disease
Heart failure or previous myocardial infarction
Clinical or ECG features suggesting arrhythmic syncope
Exertional syncope
Palpitations preceding syncope
Family history of sudden cardiac death
Non-sustained ventricular tachycardia
Evidence of atrioventricular block
Bifascicular-block
Pre-excited QRS complex
Prolonged or short QT interval
Brugada pattern
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3.

Orthostatic hypotension is characterized by an
inadequate physiologic response to postural
changes in blood pressure that decreases cerebral
perfusion. A wide variety of conditions can cause
postural hypotension, with two major mechanisms
including autonomic failure and volume depletion.
Autonomic failure is further subdivided into intrinsic
and extrinsic. Intrinsic causes include neurodegenerative diseases (ie Parkinson’s dementia) or
neuropathies (i.e. diabetes) while extrinsic causes
include medications (i.e. alpha-blockers, phosphodiesterase inhibitors, or vasodilators).4 In comparison,
severe intravascular volume depletion (i.e. dehydration
or blood loss) can lead to syncope due to functional
failure of the system despite having normal functioning
autonomic reflexes. Common symptoms of orthostatic
hypotension include dizziness, lightheadedness,
weakness, fatigue, or nausea.
Cardiac syncope is often the most concerning as it
can occur without warning leading to major
morbidity and mortality. It often occurs either with
conduction system disease (i.e. brady- and tachyarrhy thmias) or in the presence of structural
abnormalities such as valvular disease or cardiomyopathies. Bradyarrhythmia can develop from natural
pacemaker dysfunction or the development of heart
block. Tachyarrythmias can be subdivided into either
supraventricular or ventricular in origin. Supraventricular
tachycardia usually causes palpitations but rarely
causes syncope. In contrast, ventricular tachyarrythmias often cause syncope. Valvular heart disease,
particularly aortic stenosis, can lead to syncope
which most often occurs during exertion.

Typically, in older adults, cardiac syncope is often seen
in patients with preexisting cardiovascular or structural
heart disease and is often sudden without any prodrome.
Common symptoms include palpitations, chest pain,
and shortness of breath.
After a syncopal episode, the essential next step is to
establish the etiology. For nearly all patients, the initial
evaluation for syncope should include obtaining a
comprehensive history, complete physical examination,
and review of an electrocardiogram (ECG). A transthoracic
echocardiogram is useful to evaluate for the presence
and severity of structural heart disease if structural heart
disease status is uncertain, after completion of a history,
physical examination, and ECG. Additional diagnostic
evaluation, if indicated, should be individualized based
upon the suspected etiology of syncope.
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Wherever the initial syncope evaluation leads, one must
determine whether the affected individual needs
in-hospital care for further evaluation and/or initiation of
treatment. The primary factor determining whether the
patient with presumed syncope should be hospitalized is
the individual's immediate mortality risk. Patients can be
classified as high risk (requiring admission), intermediate
risk (admission is case-by-case), and low risk (can be
outpatient). See table 2 for risk stratification.5 In all cases,
arrangements for prompt outpatient care is essential.

KEY POINTS
Have a high degree of suspicion for cardiac syncope
when a patient presents with syncope without prodomal
symptoms. A comprehensive history, complete physical
examination, and review of an ECG is essential. High risk
patients as identified by a history of preexisting cardiovascular disease or structural heart disease or baseline
abnormal ECG should be hospitalized for further
evaluation and treatment.
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White Paper: Improving Handoff Culture
in Intensive Care Unit to Floor Handoffs
Grant Turner, MD, Kristin Lohr, MD, Andrew Brown, MD, Allison Greco, MD, and Rebecca Jaffe, MD

ABSTRACT
The frequency of handoffs between providers has
increased since the 2011 Accreditation Council for
Graduate Medical Education (ACGME) work hour
restrictions, generating concerns over the quality of
these handoffs and their impact on patient safety. At
Thomas Jefferson University Hospital (TJUH), the 2016
Safety Culture Survey revealed that across all specialties,
many residents felt that “things fall through the cracks”
when transferring patients from one unit to another. The
interdepartmental Housestaff Quality and Safety
Leadership Council (HQSLC) at TJUH sought to improve
handoffs at our institution and identified two areas of
focus: (1) standardizing the language of handoffs with a
commonly accepted handoff technique (IPASS), and (2)
standardizing the process of handoffs from the ICU to
the floor. Qualitatively, resident comfort with handoffs
improved with no adverse impact on time to patient
movement between units. This project demonstrated
the difficulty of changing the handoff culture at an
institution, establishing lasting change via a new EMR
system, and training housestaff of a new handoff method.
Future directions include monitoring compliance with
the new standardized handoff curriculum, and
determining whether these efforts and interventions
translate to improved patient safety at our institution.

BACKGROUND
The frequency of handoffs between providers has
increased following the implementation of the ACGME
work hour restrictions. In this context, properly structured
and timed handoffs are essential to patient safety now
more than ever.1 Despite this, studies have shown that
errors in communication of code status, medication
allergies, and changes to plan of care are common;
errors which can lead to adverse outcomes to patients.2
Improving the quality of handoffs between providers is a
growing priority in an effort to reduce medical errors. In
alignment with these goals, the standardized handoff
curriculum known as I-PASS, a mnemonic for “illness
severity, patient summary, action list, situation awareness,
and synthesis by receiver” has been validated in
single-center and then multi-center trials which showed
a reduction in medical error rate by 23% and the rate of
preventable adverse events by 30%.3,4

At TJUH, the 2016 Agency for Healthcare Research and
Quality Hospital Survey on Patient Safety Culture (AHRQ
HSOPS) was administered to 869 house staff. Of 639
respondents, only 43% viewed handoffs and transitions
favorably across all specialties. 37% of residents felt that
“things fall through the cracks” when transferring
patients from one unit to another. The ACGME’s Clinical
Learning Environment Review (CLER) committee
regularly reviews the culture of handoffs at training
programs and had also identified this as an area for
improvement in their 2015 report to TJUH, specifically
identifying ICU to floor handoffs as an area of weakness.
In this context, the HQSLC, a group comprised of 30
house staff from 15 departments which seeks to
strategically impact key quality and safety issues across
the institution, chose to focus their annual project on
improving transitions of care at TJUH. This interdepartmental working group identified the following root
causes affecting the safety of handoffs and transitions of
care at TJUH: 1) lack of standardization in handoff
content and transfer process, (2) variation in handoff
training curricula between training programs, and (3)
failure of the former electronic health record to reinforce
best practices or ideal processes. To target these root
causes, a specific focus was put on standardizing house
staff handoff practice using the ICU to floor transfer as a
prototype, as well as standardizing the content of
handoffs used by house staff across the institution
through implementation of the IPASS handoff curriculum.

INTERVENTION
An ideal handoff should be safe, timely, effective,
efficient, equitable and patient-centered (STEEEP). 5
With this in mind, we proposed the following 4-tiered
model to implement change to the current house staff
training and practice of handoffs at TJUH:
1.

Build Momentum: Identify department-based
champions, to include a resident and faculty
member dyad.

2.

Standardize Curricula: Create a training module for
use in Jefferson GME programs, based on the
framework described by the I-PASS study group,
and incorporating both didactics and simulation
exercises facilitated by resident peers.
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3.

Assess Proficiency: Develop a framework to assess
learner mastery and provide longitudinal feedback
regarding performance.

4.

Reinforce Compliance: Best practices should be
made easy to follow through intentional process
design, health IT, innovative team structures, and
feedback to frontline providers.

In order to support step 1 of the model, a faculty
member in every core GME training program was
selected to participate in TeamSTEPPS Master Training.
Evaluation of the existing workflow for ICU to floor
handoffs at TJUH identified barriers to safe transfers, as
well as existing processes that could be harnessed to
reinforce high reliability and safe communication. A high
degree of variation in the ICU to floor transfer process
was found in the following areas: (1) timing of the
handoff, (2) incorporation of best practice of using both
a verbal and written handoff, and (3) use of closed loop
communication between sending and receiving teams.
The workgroup determined an ideal workflow for a safe
ICU to floor transfer should include: (1) bedside
evaluation by the ICU team and documentation of this
in the medical record prior to transfer, followed by (2) a
verbal and written handoff between sending and
receiving residents, and finally (3) review of patient
orders and placement of an order (physician staff
information) signifying that a handoff had occurred and
identif ying the new primar y team. To improve
compliance with this new process, a new hard stop was
created in the transfer process restricting a patient from
moving to the new unit until the order review and
handoff was completed by house staff. Residents
staffing the ICU as well as nursing and physician
leadership in the ICU were educated on the intervention
and process change prior to its implementation.
Residents were surveyed at the end of each month of
the pilot to determine barriers to behavior change.
To evaluate compliance with the process change, chart
review was done to determine frequency of the bedside
evaluation and ensure the order for team staff
information change was placed by a member of the
receiving team. Data from the patient flow management
center on time from assignment of floor bed to transfer
out of the ICU was also analyzed to evaluate effects on
total transfer time.

RESULTS
Prior to the process intervention, zero patients had a
bedside evaluation prior to leaving the ICU. After
implementation of the new process, 13.6% of patients
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transferred out of the ICU had a bedside evaluation
completed and documented in the medical record by
the ICU team prior to transfer. Debriefing with house
staff in the ICU revealed barriers to compliance with this
process. First, it was felt that too much time was required
to complete the bedside evaluation, and that this
detracted from the residents’ ability to care for other
critically ill patients or be present on rounds. Additionally,
many transfers occurred overnight when the covering
resident was less familiar with the patient’s plan of care,
and staffing ratios are reduced which exacerbated the
time burden of this process.
At the beginning of the new structure, zero patients had
their staff information changed by the receiving team.
Following implementation of this process change, 50%
of patients had the updated physician staff information
order placed by the receiving team, signifying that the
floor team had received a verbal and written handoff
prior to the patient leaving the ICU. Analysis of patient
flow data before and after the pilot demonstrated no
significant difference in time to move a patient once a
bed had been assigned.

DISCUSSION & SYSTEMATIC BARRIERS
TO IMPROVEMENT
Handoffs are a critical component of quality care of the
hospitalized patient, and require constant vigilance to
maintain high quality given their increasing frequency.
At our institution, handoffs from one unit to another
within the hospital were identified on many levels to be
an area needing improvement, and the HQSLC set out
to demonstrate that standardization of the content and
process of handoffs is crucial to improving the safety of
our patients.
Although our pilot for a new transfer workflow resulted
in only a modest behavior change in practice, it
stimulated significant dialogue around handoff practice
and culture. We believe this housestaff driven discussion
helped to make safe handoffs an institutional priority.
With this project occurring just prior to a transition to a
new electronic medical record, our results informed the
creation of a new electronic documentation workflow
for patient flow from the ICU to the floor affecting
lasting culture change at our institution.
With the proven validity of IPASS as a standardized
method for effective handoffs, we were able to
demonstrate to GME leadership at our institution the
necessity to provide this training to all house staff. As a
result, all incoming interns in 2017 were trained in IPASS
using a curriculum that was developed with abbreviated
IPASS materials specific to our hospital system.

We were met with several large barriers implementing
the ICU to floor handoff change. The extensive
heterogeneity of handoffs in practice seemed to be the
greatest barrier to improvement. Handoffs and
transitions of care are by nature heterogeneous.
Different providers require different subsets of
information and have different priorities when giving
and receiving handoffs. However, best practices have
been described and the creation of a shared mental
model, where all providers have the same expectation
of content and process of a good handoff, is crucial to
excellent patient care.
Conceptually, handoffs can either be viewed as black
and white (“Patient is mine, and now he’s yours”), or they
may acknowledge a “grey period” of shared responsibility. Structures, such as closed units, and stressful
working conditions reinforce a black/white mindset,
and opportunities for collaboration to meet the patient’s
needs may be missed.
In addition, we found that leadership buy-in for
improvement in handoff culture varied across
departments and units. We found that driving change
from below in this area is difficult without a mandate
and support from faculty and senior house staff. Buy-in
needs to be achieved at all levels of interprofessional
practice, departmental and educational leadership, and
hospital administration. Unfortunately, lack of support
for process change can arise from various concerns,
such as pressures to meet benchmarks for time to
patient transfer, at the expense of good quality handoffs.
In reality, the need for rapid and efficient transitions in
care should make the role of clear, effective and
standardized communication that much more vital.

Finally, a broad push for handoff education across the
institution will help to create a common language and
vocabulary for effective communication and higher
quality handoffs. Training incoming and junior staff
appears to be the most feasible approach to encourage
and reinforce behavior change from the ground up, as
was completed at our institution. To ensure continued
lasting success in handoff safety initiatives at TJUH, the
HQSLC has continued to disseminate IPASS education
to senior residents across all GME training programs,
with a total of nine programs trained to date. In order to
evaluate the quality of handoffs, including the appropriate
use of the IPASS format, HQSLC members are currently
participating in formal interdisciplinary handoff
observations involving real time, direct feedback.
Further research efforts are necessary to continue to
evaluate the effect of standardized handoff training in
improving the perception of handoff safety at TJUH and
its role in improving patient safety.
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INTRODUCTION
Colin: This year marks the 19th volume of Jefferson’s
annual publication spearheaded by Internal Medicine
residents and supported by its fellows. Our Editorial Board
includes Neha, Debbie, Anita, Brianna, and myself. Our
mission is to further medical knowledge by sharing each
other’s observations and studies both through our
publication, which you can find online, as well as through
annual discussion at Grand Rounds.
This year, we’ve chosen to focus on our roles as providers
in the midst of the National Opioid Epidemic. The
National Institute on Drug Abuse has reported that the
number of opioid-related overdose deaths from both
illegal and prescription opioids has risen in our state over
the last 15 years. This information is available for each
state online. While addiction has been a nationwide
issue for centuries, provider practices and societal
attitudes in relation to opioids has greatly varied. We’ll
introduce you to our panelists, giving a very brief
overview of the history of opioid use in our country, then
turning the discussion over to them.

Today, we have Dr. Abigail Kay, Assistant Dean of Academic
Affairs and Undergraduate Medical Education and
Assistant Professor in the Department of Psychiatry and
Human Behavior. Ms. Meghan Morley is the Lead Patient
Navigator at the Center of Excellence at the Narcotic
Addiction Rehabilitation Program (NARP) in the Division of
Substance Abuse. Dr. Rachel Nash is a current Chief
Resident in the Department of Internal Medicine. Ms. Kate
Siddiqi is a social worker at Jefferson. Dr. Brooke Worster
is an Assistant Professor of Palliative Care in the
Department of Family and Community Medicine. Dr. Jill
Zavodnick is a hospitalist at Jefferson. Drs. Kay, Nash, and
Zavodnick and Ms. Morley are members of Jefferson’s
Opioid Task Force, established in the fall of 2017 to provide
structure, focus, and direction to Jefferson’s response to
the current Opioid Crisis. No one involved with these
Grand Rounds has any relevant disclosures.
Brianna: First we’re going to go over some definitions so
we can all be on the same page as we move forward in
our discussion. “Opiate” is a term used to describe any
drug derived from actual opium. “Opioid” was a term
initially used to describe synthetic or semi-synthetic
versions of opiates but has now come to encompass any
agent which binds to opioid receptors in the CNS and GI
tract, including natural, synthetic, and semi-synthetic
drugs. The body produces natural, endogenous opioids
such as endorphins which are unable to independently
cause respiratory depression or adequate pain relief in
extreme circumstances. Opium alkaloids include
morphine and codeine; semi-synthetic opioids resemble
the structure of opiates and include heroin, oxycodone,
and buprenorphine; and fully synthetic opioids which
don’t resemble the structure of opiates at all include
methadone.
Prescription and illegal opioids can lead to patterns of
tolerance, dependence, and addiction with chronic use.
We’ll go over those three terms as well. Tolerance
suggests that a person require higher and/or more
frequent doses of drug to achieve desired effects such as
pain control. Dependence implies that one’s neurons
only function normally in the presence of drug and thus
that its absence results in withdrawal symptoms. Addiction
refers to compulsive or uncontrollable drug-seeking
behavior despite harmful consequences—either at work,
in relationships, with one’s health, or with the law.
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Colin: The Smithsonian published an article just last week
called “How Advertising Shaped the First Opioid Epidemic,
and What It Can Teach Us About the Second.” It sets the
stage in the 1800s, when physicians and manufacturers
who recognized the effectiveness of morphine as a
painkiller began incorporating it into many drugs. There
was no Food and Drug Administration (FDA) to regulate
safe and standardized production yet, so medicines were
sold without a full listing of their active ingredients and
often without need for a doctor’s prescription. Cocaine
and alcohol were also common additives to popular
medications then.

and fentanyl were later released for chronic non-cancer
pain and again purported to be less addictive. Educational
programs funded by pharmaceutical companies and
supported by such institutions as the American Pain
Society (APS) designated pain as “the fifth vital sign” as
recently as the 2000s and prescription opioid use peaked
in 2010 with 82 prescriptions for every 100 persons. This
takes us to present day; with the rise of opioid-related ED
visits for nonfatal overdoses as well as actual deaths, the
pendulum has swung back in the direction of discouraging
opioid use and the establishment of the Prescription Drug
Monitoring Program (PDMP).

Morphine was heralded as a cure-all, recommended by
physicians at the time for everything from wounds
obtained by soldiers during the Civil War to the menstrual
cramps and teething pains of their wives and children.
Use of IV and oral formulations of opioids was ubiquitous
and most patients who sought prescriptions were of
respectable social backgrounds. Once doctors and
journalists began to take note of the addictive nature of
these medications, the Pure Food and Drug Act was
created in 1906 and eventually gave rise to the FDA.

TRANSCRIPT

Brianna: Now I’m going to walk us through a timeline of
opioid development, which stretches back to the 1800s
all the way to today. This timeline is interesting because it
clearly demonstrates the swinging pendulum in regards
to the support and criticism surrounding the use of
opioids. We’ll start way back in the 1800s when morphine
was first isolated from plant. Merck began marketing it in
the 1820s in a pill form. Codeine was first isolated in the
1830s and used for cough. Then the syringe was invented
in 1850s and you can see morphine really came into use
in its IV form during the Civil War in the 1860s. Then, in
the 1870s, heroin was invented and marketed as a safer
drug. You’ll see this theme as we go forward—the
realization that a certain opioid or type of opioid was
addictive, government intervention, then the production
and marketing of a “safer drug.” Next, as awareness of
opioid addiction grew in the 1900s, the act giving rise to
the FDA was established. This reduced the use of
morphine both as prescribed and over-the-counter
medications, but doctors were instead encouraged to
employ “less addictive” painkillers such as oxycodone and
methadone in subsequent years.
In the 1970s, pharmaceutical companies which had
previously limited their marketing to physicians also began
redirecting their advertising to consumers directly which
contributed to a nationwide clamor for these
semi-synthetic and thus reportedly safer agents. When
the addictive nature of these agents were subsequently
elucidated, the War on Drugs was declared and the “Just
Say No” campaign launched. Just a decade later, the
Drug Enforcement Agency was also established at this
time. Extended-release versions of morphine, oxycodone,
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Colin: In the last couple years, President Trump has
declared the Opioid Crisis a national epidemic and public
health emergency, vowing to dedicate $13 billion to new
resources for addiction treatment, physician education
on appropriate prescribing, and prosecution of drug
traffickers. Most recently, the CDC has released an annual
surveillance report of drug-related risks and outcomes for
2017, reflecting on the previous year. We’ll leave up these
statistics as we begin our conversation with our panelists,
centered on our role as providers in the midst of the
Opioid Crisis. To begin, I think it would be nice to just go
down the line and explain your role and experience taking
care of patients in the Opioid Crisis.
Dr. Kay: I’m Dr. Abby Kay and from 2005-2015, I was
the Medical Director of NARP. When I became the Dean,
I switched to being a regular, everyday doctor there and
I teach both locally and nationally about how to use
medically-assisted treatment options and how to treat
addiction in general.
Dr. Worster: Hi, I’m Dr. Brooke Worster and I live in the
palliative care world so I sort of straddle this interesting
bifurcation of opioids in that we employ them often in
end-of-life care. I also live in the world of cancer pain
management and, I’m happy to report, cancer survivorship
which entails a lot of substance abuse disorders which
are often iatrogenically created. I’m a part of the Task
Force here and deal with a lot of substance abuse
disorders, opioid abuse disorders, but have to maintain
some availability because they aren’t all bad.
Dr. Nash: I’m Rachel Nash, I live in the resident world and
am one of our current chiefs. I became interested in this
topic mainly out of frustration, being on Green medicine
and being a night Medical Admitting Resident and feeling
like I was taking care of the same patients over and over
again that struggled with opioid use disorder. As a result of
that, I did additional training in addiction medicine in Boston
and have been involved in the Task Force ever since,
focusing on resident education and increasing the use of
the PDMP and familiarity with suboxone on campus here.

Dr. Zavodnick: I’m Jill Zavodnick, I’m one of the hospitalists
here which makes me a very frequent inpatient prescriber
and occasional short-term outpatient prescriber of
opioids. I’ve seen lots of the medical complications of
addiction as well as the medical consequences of our
inability to treat pain very well, so that’s part of what got
me interested in this issue—the consequences of
hospitalized addicted patients with withdrawal symptoms
that we’re not great at managing which makes us not
great at managing their other medical problems. My goal
is to help inpatient providers figure out what to do with
people who are suffering from withdrawal when they are
in the hospital partially to facilitate their medical care and
then figure out how we can use our inpatient visits as a
way to help get people more engaged and linked into
recovery.
Ms. Morley: Hi everyone, I’m Meghan Morley, the Lead
Patient Navigator at the Center of Excellence for the
Department of Psychiatry in the Division of Substance
Abuse. I’m a professional counselor and started at NARP
as a therapist doing substance abuse counseling there
for methadone maintenance patients. The Center of
Excellence is a grant that was given to the university
from Governor Tom Wolf to help connect people with
treatment through warm handoffs, and most of my efforts
are focused at Methodist Hospital but also at Main
Campus. I also work with offices that prescribe suboxone
to help people connect with counseling services, so I’m
happy to be here today to talk about our service and how
we can provide you with support in connecting your
patients with treatment.
Ms. Siddiqi: I’m Kate Siddiqi and I’m an inpatient social
worker and have been here for 14 years as of today itself.
We have a large number of patients as you’ve all
mentioned who have cycled back through, and it’s very
frustrating but we’ve had success from Meghan and the
Center of Excellence connecting people to the outside.
There are barriers that we’re slowly trying to whittle away
at, but they are institutional and outside of our system, so
it’s a group process to work through those together.
Colin: Thank you. What Brianna and I will do is ask a few
questions before punting it to the audience to ask some
questions too. Our first question is, How has increased
awareness of the opioid epidemic changed your practice
of prescribing opioids and counseling patients on their
appropriate use.
Dr. Nash: In the inpatient world, the pendulum has swung
from using opioids to really try other alternatives before
going to opioids for pain management. Most providers
are more aware of the risks and benefits of using opioids.
What’s astounding is that the more I read about chronic
opioid use, the more confused I’ve become. I do worry
about the limits that are being proposed on the number
of morphine equivalents providers can prescribe, leaving

a patient population that are like pain refugees in a way. I
think we really need to evaluate prescribing patterns of
physicians as a whole at our institution, which we’re
beginning to do, and identify variations in practice habits.
This is much like the tenets of quality and safety—where
you evaluate your performance, see where your outliers
are, and address them. Our Opioid Task Force looked at
surgical data, habits of surgeons who were prescribing
narcotics after routine procedures such as cholecystectomy. We called patients a few days after discharge
and found that 60% of these patients’ narcotics were not
being used. That’s a real area of us to evaluate our
prescribing habits, what patients really need, and reduce
the number of opioids in the system that may theoretically
decrease diversion. That’s certainly a way that some
patients become addicted. So I would say that the
pendulum is swinging and prescribers are aware of risks,
but still work needs to be done in evaluating variations in
prescribing patterns.
Dr. Worster: Personally, I have changed my prescribing
practices significantly; I live in the outpatient world. I
probably prescribe opioids nearly every single day. I take
care of patients with cancer, I take care of patients who
are dying. But I think there’s a couple of things that have
really meaningfully contributed to the conversation that
I’m having a lot more with patients. One of them is the
PDMP and I’m so frustrated that Pennsylvania was one of
the last adopters of this nationwide—and for a while we
couldn’t actually query New Jersey or Delaware, so you
had a partial picture but not even the whole picture.
Finally, that’s in place and I think that is something that is
just best practice; everyone that we give a medication to,
we should be looking. The other thing is that public
awareness. I think public understanding of the crisis has
people coming into my office saying, “I’m scared of
opioids.” I just left a patient today who is 70 years old and
has metastatic prostate cancer who basically became
non-ambulatory because he had such bad bony pain but
didn’t want to take opioids because he was scared of
becoming addicted. So as the pendulum swung so far
one way, with pain being the fifth vital sign and us saying
“Everyone needs opioids,” I also do caution that we can’t
throw the baby out with the bathwater here. There is
some goodness to this, and I think the best change that
could be happening out of all of this in terms of prescribing
patterns is that it really becomes an informed conversation
between the patient and the provider. We have to
understand what is driving patients who are either taking
the medication or not, how to take it safely, and how to
get rid of it if they’re not taking it. Eighty percent of the
opioids people take are outside of one physician
prescribing them, so we’re missing the boat in connecting
the dots between “What pill am I going to write for you
today?” and what happens beyond that setting.
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Dr. Nash: I think two things the audience should be aware
of is that there is now a Take-Back box in Jefferon’s
apothecary, open the same hours as that pharmacy,
where you can bring back your medications. You can tell
your patients that the box is available now. I also just got
off the phone with Dr. Jeff Riggio who wanted me to
inform you that the PDMP is going to be integrated into
Epic very soon. You’ll be able to press Care Everywhere
and see the PDMP data if you are registered. This is
another reason Dr. Zavodnick and I are really pressing
house staff to become registered with PDMP because of
its value.
Dr. Kay: One comment I want to make—and, yes, there
are exceptions, but in general—for every patient that I’ve
admitted to the Methadone Clinic who has said, “I had no
addiction until I got the Percocet for this surgery,” that
hasn’t been the case. The problem is, there are things that
are addictions that we don’t consider addictions; when
they were 12 they were smoking a pack a day of cigarettes
or using alcohol heavily or using marijuana on a regular
basis. We sort of throw those out the window. My feeling
is that these are really important things to pick up on and
think about, I think the history is the piece we’re often
missing. I’m not saying that if a patient has that history, it
puts them at risk for future addiction. It’s not that you
wouldn’t give them opioids if necessary, but you might
have a different conversation with them. The thing that
drives me crazy is that I’ll come see one of the methadone
patients at the hospital and when I look at the H&P, it’ll say
“One pack a day of cigarettes, three glasses of wine
occasionally.” By definition, they’re on methadone; they
have a significant addiction history with opioids and
there’s nothing documented. I see a great tobacco and
alcohol history but that really isn’t a surrogate for an
addiction history. I think we have to be much more
thoughtful about the history.
Dr. Zavodnick: I think Dr. Kay made a really good point
about naming the problem, and that’s a big change that
I’ve seen since I was a resident here not terribly long ago.
I thought that when I was a resident our notes would
sometimes inaccurately document the problem, like
“IVDA” or IV Drug Abuse which would be listed in the
social history but nowhere else. We’d have Night Float
getting calls in the middle of the night and who would tell
us, “They’re always asking for this or that,” but no one was
actually naming a diagnosis for them. What I’m seeing
more and more is that when we’re documenting or
talking to the patient or talking to the team, “Opioid Use
Disorder” or “Opioid Addiction” is actually a part of the
problem list and is something we create a plan to address.
Our conversations with patients include what we can do
about symptom management and what we can expect
about pain needs during the admission. What we need to
get better as providers in the Opioid Crisis is to start
treating opioid use disorder as a diagnosis and as a
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problem instead of as some background issue that’s really
only going to be handled by the intern taking pages
overnight.
Colin: We’ve already touched on this a little bit, but what
differences have you noticed in patient attitudes towards
opioids since the opioid epidemic was declared a national
priority?
Dr. Worster: We jokingly say that I’m either begging
someone to take a milligram of morphine or I’m begging
them to stop taking 7,000 milligrams of morphine. That’s
certainly an exaggeration, but I think patient attitudes
have diverged very broadly because of this crisis. Some of
them have this awareness and are scared—and I think we
should all have some healthy fear of opioids—but there
are other patients who say, “I don’t care what you tell me,
this is the only thing that works for me and I’m going to
take it and be damned if you’re going to take it away from
me.” Patients are nervous about it because it’s in the news
and everyone’s talking about it, and all of a sudden, even
the process of getting pain medications is changing. You
can’t go to the ED and walk away with 30 days of a
prescription anymore. I find that it is a more emotionallycharged patient that I see when I’m talking about opioids,
one way or the other. It’s becoming more of a difficult
conversation and I think it’s becoming really important
that we all participate in with these patients. It should be
something that is noted on the problem list and something
we talk about with them directly—not as shaming, not
something that gets marginalized, but something that is a
part of how we best take care of them.
Colin: How does your management differ for patients
with acute care needs as compared to patients admitted
on chronic opioid therapy?
Dr. Zavodnick: I have a very low threshold for calling the
Acute Pain Service. I do remember being taught in medical
school about how likely we are to underdose patients with
opioid dependence and that’s something I worry a lot
about with increased awareness; as we swing the
pendulum potentially too far in the other direction and
find ourselves policing people with chronic pain, deciding
whether their pain is legitimate—“Well, let’s not given them
IV,” “Let’s make sure that they have an outpatient prescriber
so I’m not the one prescribing it.” I can see a lot of fear
from providers as well. I have a low threshold to ask for
help in treating acute on chronic pain because I don’t
know how well I’m going to be able to treat pain with the
medications I have without causing respiratory depression
and so I think about ketamine early. These patients need
more aggressive treatment, not less.
Dr. Nash: It’s almost easier inpatient, because your patient
is monitored. You don’t want something bad to happen
to your patient, but when he or she is on a monitored
unit, it’s easier to make adjustments to treat acute on

chronic pain. My thinking about some of these patients
has changed; I’ve come to realize that patients on
long-acting opioids need that medication almost to feel
normal and function as their normal selves.
Dr. Zavodnick: I’ve also seen the lines between acute and
chronic pain blur; when I see a diagnosis of “Acute on
Chronic Pain,” I’m not sure when we have acute pain and
when we have inadequately managed chronic pain. I
think it’s great that we’ve become more aware of the risks
of narcotics but there are also people who want, expect,
and maybe need these medications who aren’t able to
access them. In the same way I sometimes have difficulty
transitioning heroin users to the outpatient world, I
sometimes have difficulty transitioning chronic pain
patients to the outpatient world because they’re started
on narcotics for chronic pain in the hospital and I’m not
able to find anyone willing to follow them.
Dr. Kay: I just want to make a few quick comments: The
first is to remember that the goal for patients on
methadone maintenance is to get them on a blocking
dose such that if they used any opioids, they would not
get high off of them but would still get pain management.
They can get opioids, the important thing is to make
sure they don’t feel as though it is “stirring up” their
addiction, to ask the question. The other thing is that
when managing patients’ acute or chronic pain, I like to
think of it as a pie and explain to them, “I can’t give you
one pie, but I can give you eight different slices of
different pies to make up a whole pie.” It’s not going to
be that one medicine takes care of everything, pain
management involves a multimodal approach. I also
want them on standing NSAIDs because that will greatly
reduce their opioid needs.
Dr. Worster: I think that’s a great point and emphasizes
the need for education about what pain is. The pathophysiology of pain is very different depending on whether
you’re talking about inflammatory pain or neuropathic
pain or visceral pain. I didn’t get that education and I think
that’s crucial. If you’re trying to treat neuropathic pain with
opioids and the patient’s requiring more and more, no
kidding—neuropathic pain isn’t really responsive to opioids
based on the pathophysiology. There’s a reason why, with
inflammatory pain, you get more bang for your buck
using NSAIDs as opposed to opioids.
Dr. Kay: One more take-away is to ask, “What’s the
patient’s goal with the medication?” One of my NARP
patients was going for a root canal and I suggested he
take 600 milligrams of ibuprofen before the lidocaine
wore off. He told me, “I don’t mind the pain, I want to not
care about the pain.” The opioid would have done that
while the NSAID would not have had that effect.
Sometimes patients take opioids to knock them out, help
them sleep. It’s always worth asking what the patient’s
goal is with the medication.

Brianna: Kate and Meghan, would you be willing to talk
with us about the community resources available to get
our patients plugged in?
Ms. Morley: Sure, I have information up here about our
team and we’re working to get ourselves listed as an
official Consult in Epic. As far as Jefferson goes, we do
have two methadone clinics, the Family Center for
pregnant and parenting woman as well as NARP for
everyone else. My team doesn’t just refer to Jefferson
resources. When patients are admitted to either Jefferson
Main Campus or Methodist, I come in and really lead with
motivational interviewing. Something that I have the
luxury of is time and I know that not everybody has that.
Social work sure doesn’t, you don’t as providers. I
understand that. I can spend 20-30 minutes just having a
conversation with patients about their use and life and
traumas before I even say the word “treatment,” and I
think that having the time to build that relationship is really
important to getting people to that motivational place
where they are open to discussion.
Once patients have decided that they are ready for
treatment, we work in tandem with Social Work to refer
them to appropriate programs—be it methadone,
suboxone, vivitrol (medication-assisted therapies), or even
if they want to go into counseling, we can facilitate those
warm hand-offs and make sure that there’s no gap in
care. The day that they’re being discharged from the
hospital or the following day, they’re being admitted to
whatever program we have decided to send them to. We
can also link them to outpatient providers that aren’t in
the “clinic world” or the “substance abuse world” as a lot
of patients who are professional aren’t going to be able to
engage in those programs because there are often group
or individual therapy sessions that run during the day that
a working individual isn’t going to be able to attend. We’re
able to have conversations with people about what their
life looks like and what program makes the most sense
for them. One of the biggest barriers for us is when a
patient doesn’t have a urine drug screen (UDS). A patient
can’t be admitted to any type of medication-assisted
program without a urine drug screen that’s positive for an
opioid. That’s something we’ve been preaching and
pushing because the lack of a UDS stops people from
being admitted to the program they chose that next day.
Basically without telling them to, we know and they know
they’re going to have to go out and use before being
admitted to these programs. There are other barriers to
these programs like identification and it’s something to
keep in mind when prescribing medication-assisted
therapies as an inpatient—you need to think about the
other documents that are necessary to continue these
therapies as an outpatient. These are the sorts of issues
that my team deals with and we want to be known!
Someone once told me that we’re the best-kept secret
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and Jefferson and we really don’t want to be. We’re trying
to get our name out there as a resource for you.
Dr. Kay: You make a very good point about there being
three types of opioids—natural, semi-synthetic, and
synthetic. Each has a different urine drug screen, you
have to specifically test for methadone and buprenorphine.
If I use heroin today and you just test me for methadone,
I’m going to come up negative and vise-versa.
Ms. Siddiqi: To reinforce what Meghan said, we absolutely
need the UDS. Without it, I can refer until the cows come
home and nothing will happen. The other barrier, as she
mentioned, is the lack of ID. Some clinics are becoming
more receptive to expired ID or are getting copies from
previous treatment centers, but not everywhere. Today I
actually called my colleagues at an agency named BHSI
which helps the uninsured get insurance and, in the
interim, guarantee payment to a clinic so we can get
someone directly in from discharge here who is uninsured.
They have remained very strict about identification, so if
there’s no photo ID, our ability to refer to them at the
moment is limited. I’ve had some arguments with
physicians who prescribe methadone as an inpatient to
keep people in the hospital to receive the rest of their
medical care. On the other hand, starting someone that
we cannot comfortably get into ongoing care after
discharge raises some other ethical issues as well, because
no one will prescribe methadone to someone who is out
in the community but not connected. Another dilemma
that we have as an inpatient related to patients who are on
methadone and need IV antibiotics or wound care for an
extended period of time. We are kind of up the creek as
there are only two facilities in area that accept these
patients as inpatients; one is Kensington Hospital, the
other is Valley Forge. Kensington is in a position now
where they can cherry-pick and only accepts patients on
Medicaid-HMO (not state Medicaid). Valley Forge is difficult
to get into. If you have a patient on state Medicare, we’re
kind of screwed also. Medicare seems to have a bizarre
notion that older people no longer have substance abuse
issues and that’s something that really needs to be
addressed as a society. It’s really criminal, in some respects,
that there is no ongoing access for these patients.
Dr. Kay: Even if you’re not entirely sure the patient will be
followed up as an outpatient, I’d still put someone who
addicted to opioids and is agreeable on methadone
because if you don’t, you run into two problems. First, if
someone just had a heart attack, having them in
withdrawal is really not safe cardiac-wise, with their pulse
racing and blood pressure up. The other issue is that
they’re at high risk of leaving against medical advice. To
get them the proper care and for medical safety, my
feeling is you should be putting them on methadone.
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QUESTIONS
Dr. Emily Stewart: What’s the highest we can safely do
that and then discharge them if they don’t intend to quit?
Dr. Kay: There is no magic number. When I first started
here, I was obsessed with the practice that everyone who
was started on methadone in the hospital had to be
tapered off before discharge. Since then I’ve discovered
that the taper doesn’t really matter and the way that I
think about it now reflects something I’ve picked up from
a colleague of mine—which is to say that they were using
before they came in, unfortunately as much as I’d like to
get everyone into treatment, not everyone is ready and
the reality is that some people are going to leave the
hospital and use again. Another thing to remember is that
often patients’ friends will bring them things into the
hospital. So there is no magic number, but there are, of
course, safety issues with higher and higher doses of
methadone. We could have a whole separate Grand
Rounds about inpatient management of methadone.
Dr. Zavodnick: This is about to get much, much easier.
The treatment subcommittee has been working on a
guideline for inpatient management of patients in
withdrawal. There are a couple different pathways,
including one for patients interested in seeking medicationassistant therapy in the long-term and for whom you’ll
need to consider outpatient care up front. The Center of
Excellence is really great at this, thank you for bringing to
the forefront these new resources for our patients and
making the bridges to outpatient care stronger and
stronger. We’ve included in the guidelines some tips for
the providers overnight, because Psychiatry and Social
Work is all well and good in the morning but we want to
interns on Night Float to have support in caring for
patients’ withdrawal symptoms overnight and at least
begin to have a conversation with the patient about
whether he or she would be open to methadone or
suboxone long-term which could then be started as an
inpatient. We’ll have guidelines about how to start these
medications, how to titrate them, when to call Psychiatry.
Not every patient who comes in is going to be interested
in engaging in treatment and we’re still going to have
guidelines for robust symptom management with
clonidine and Zofran, for example. Just because some
patients might not be interested in methadone doesn’t
mean we don’t want to treat their withdrawal. I think we
as front-line generalist providers are going to get a little
more support in making these decisions for our patients
and saying, “Here are the things we offer for withdrawal
management, which of these do you want to try?” and
“I’m here to partner with you on this inpatient stay and
we’re going to call the Center for Excellence to figure out
an outpatient plan, too.” I think guided inpatient
management of withdrawal and warm hand-offs to
outpatient resources make up the gold standard that we
should all be reaching for with our patients.

Dr. Sarah Rosenberg: As a healthcare system, I can’t help
but feel like we’re completely blowing this in a way that’s
baffling to me. It seems as though politicians and the
laypeople are blaming doctors for the Opioid Crisis but
do you have any tips on how to repair our therapeutic
relationships with patients?
Dr. Worster: What goes hand-in-hand with that are
conversations with patients that are like, “I want it”/”No,
you can’t have it”—this bargaining. I tell people all the
time, “I’m fine with you being angry at me. That’s okay, I
can take that. I need you to hear that all I care about at
the end of the day is providing you with care that is safe.”
Because that’s the first thing we all signed up for here, to
do no harm. I think with empathy, you can communicate
that with a patient. We can say that it’s fine for patients to
feel angry, sad, or frustrated. We hold those emotions for
them. But we need to have realistic one-on-one
conversations with patients about safety, I think that’s
where repairing those therapeutic relationships start. I
think most patients will partner with you if you provide a
safe, non-judgmental space. I think it’s a small minority
that will see you as the cause of the problem or stay angry
with you because you’re not giving them anything at all.

Dr. Kay: I have a ton of experience with this on the benzo
front and have often approached patients with terrible
anxiety by saying, “I don’t think this plan that we’ve had is
working for your anxiety. The Xanax isn’t cutting it, we
need to do better. Let’s come up with another plan.”
Dr. Suchit Bhutani: I know the emergency room (ER) is a
place of first-exposure for many patients. There are some
centers in New Jersey which have advertised “Opioid-Free
ERs,” is that something that we’ve considered or could be
changing here?
Dr. Worster: If you look at this on a larger level, the
number of total ER opioid prescriptions over the last few
years have gone down. Now, it defaults to a 72-hour
prescription instead of seven or 10 days. I don’t see how
you can provide great, individualized care to people by
making blanket statements. That’s like saying, “Listen, I just
don’t do antibiotics, so we will never give you antibiotics.”
We also can’t just stop providing good medical care. Our
ER providers are very engaged in this problem. If they see
my name in the PDMP, they’ll give me a call and I’m happy
to have that conversation with someone. That’s what we
really need to do, to increase our communication about
this problem.

Dr. Rebecca Jaffe: I’d like to commend that approach
because I think what I’ve seen over the last five years is a
discomfort about what’s happening and an unwillingness
to engage in that partnership. You’ll see people saying,
“Well, I can’t prescribe that for you,” or “My clinic won’t
prescribe opioids,” and that’s very different from a
harm-reduction strategy where you might say, “This is the
current state of where we are, this is where we plan to go
long-term, what are the steps to get there?” Talk about the
different things that we can do with patients to improve
safety and build partnership.
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RESIDENT REFLECTION

A Missed Date
Timothy Kuchera, MD

“You’re a DOCTOR, NOT a CLERK,” bellowed my attending as I blinked with bloodshot, sunken eyes. “So
use your BRAIN like a DOCTOR!” It was February of my
intern year. At this point, I was exhausted and emotionally drained. I had minimal contact with friends and family and lost all ability to converse with those outside of
medicine. My favorite hobbies now included repleting
daily potassium and ensuring that my patients had regular bowel movements. Honestly, I got so good by the
end of the year that just by walking down the hallway,
my patients would experience a rectocolic reflex and a
symphony of call bells would fill the air. It was music to
my ears. It was during this unique and trying time in my
life that I met a patient named Mary.
Mary’s admission was abrupt and unexpected. She was
69 years old and had been otherwise healthy until she
presented with two weeks of fevers and fatigue. On
admission, she was found to be pancytopenic, and a
bone marrow biopsy was performed. Shortly thereafter,
Mary was diagnosed with Hemophagocytic
Lymphohistiocytosis, also known as HLH, in addition to
a very rare T-cell lymphoma. HLH is an aggressive and
life-threatening syndrome of excessive immune
activation. A diagnosis with HLH can drastically cut life
expectancy. Mary’s dual diagnoses of HLH with T-cell
Lymphoma reduced her life expectancy to one to two
months. Despite the overwhelming odds, like any family
struck with this sudden news, Mary and her family were
hopeful that prompt treatment would alter the course of
her illness and reach a cure.
In spite of her grave prognosis, I was struck by the life
and energy that Mary exuded. Even at the age of 69 with
multiple organ failure, she would greet me every
morning with an energetic, “GOOD MORNING, BABY!”
She constantly joked with the nurses, residents and
attending physicians. She was a favorite patient among
staff. Everyone was pulling for her. One morning out of
the blue, Mary asked me where I was taking her on our
first date. Completely caught off guard I sputtered, “Well,
where do you want to go?” “I don’t know!” She shot
back, “But if it ain’t somewhere nice, you and me are
through!” When my attending heard about this, she
stated that Mary had the worst case of steroid-induced
psychosis she had ever seen…
It seemed Mary’s spirit could not be extinguished.
Diagnosed with HLH? Bring it on. Lymphoma? Whatever.
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GI bleed? Flirt with the GI fellow. One morning, a rapid
response was called for syncope. By the time I arrived,
she recovered and was cracking jokes with the residents
and nursing staff. In even the most desperate of times,
she maintained her enthusiasm and lightheartedness.
Unfortunately, this story ends the way you probably
expected. One morning, Mary was transferred to the
ICU for emergent dialysis. From there on, her clinical
course took a precipitous turn. The HLH, lymphoma, GI
bleed, UTI, pneumonia, liver failure, and kidney failure
compounded, and Mary and her family decided that
they had enough. For four weeks, Mary was poked,
prodded, biopsied, imaged, dialyzed, and filled with
cytotoxic chemicals. A mutual decision was made to
pursue comfort measures and have Mary spend her final
days in the company of her family. Coincidentally, this
decision came on the final day of my oncology rotation.
I had not seen Mary since her transfer to the ICU and
when I stepped into her room I barely recognized her.
The previously raucous, animated, jubilant Mary now lay
cachectic and motionless in her hospital bed. I stumbled
over my words as I filled the silence with superficial
conversation. I began to experience overwhelming
feelings of loss and despair as I realized our time was
short. I missed the energetic person I had come to know
and care for one month prior. If I could just see her
laugh, I thought, maybe everything would be okay. I
asked, “Mary, where are we going on our date?” What I
hoped for was a quip. What I hoped was for Mary to
spring back to life. Instead, I got something much
different. She slowly shifted her gaze to mine, pointed at
the sky and whispered, “In Heaven.” I attempted to
collect myself and managed to choke out, “Well you
better pick somewhere good!” “Don’t worry,” she said.
“I’ll have plenty of time.”
Despite our efforts, Mary passed away on April 9th,
2017. I am grateful for Mary. Her love and passion for life
were infectious and I am very fortunate to not only have
met her but to care for her as her doctor. Caring for
Mary was a privilege and truthfully reminded me of my
humanity. Doctors and nurses have all experienced that
medicine can be a draining and potentially jading
profession. My hope is that my colleagues have the
opportunity to experience rejuvenating and heartwarming
people in their practice like Mary; both in the patients
they treat and the people they work with.

